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        FcRn, the neonatal Fc receptor, is an MHC class I related molecule, functions as 
an IgG protector and transporter. Binding of IgG by FcRn exclusively occurrs at 
acidic pH, in correlation with the fact that FcRn mainly resides in acidic endosomes. 
Herein, we found an association of FcRn with invariant chain (Ii). The interaction 
was initiated within the endoplasmic reticulum by Ii binding to either the FcRn heavy 
chain alone or heavy chain-beta-2-microglobulin complex and appeared to be 
maintained throughout the endocytic pathway. The CLIP in Ii was not required for 
FcRn-Ii association. The interaction was detected in IFN-γ-treated THP-1, epithelial 
and endothelial cells, and immature mouse DCs. A truncated FcRn without the 
cytoplasmic tail was unable to traffic to early endosomes; however, its location in 
early endosomes was restored by Ii expression. FcRn was detected in the late 
endosome/lysosome only in the presence of Ii or upon exposure to IFN-γ. In 
immature human or mouse DCs, FcRn was barely detected in the late 
  
endosome/lysosome in the absence of Ii. Taken together, the intracellular trafficking 
of FcRn is regulated by its intrinsic sorting information and/or Ii chain.  
 
        Vaccine strategies to prevent invasive mucosal pathogens are being sought due 
to the fact that 90% of infectious diseases are initiated at mucosal surfaces. However, 
our ability to deliver an mucosal vaccine antigen for induction of the protective 
immunity is limited. FcRn mediates the transport of IgG across polarized epithelial 
cells. Taking advantage of this unique transfer pathway, I sought to delivery of 
antigens across mucosal barrier using IgG Fc fused proteins. It was demonstrated that 
intranasal immunization with a model antigen herpes simplex virus type-2 (HSV-2) 
glycoprotein gD fused with an IgG Fc fragment combination with CpG ODN 
adjuvant resulted in a complete protection of wild type, but not FcRn knockout mice 
that were intravaginally challenged with virulent HSV-2 186. The immunization 
induced efficient mucosal and systemic antibody as well as long lasting memory 
immune responses. These results are the first to demonstrate that the FcRn-IgG 
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Chapter 1: General Introduction and Specific Aims 
 
IMMUNITY 
        In biology, immunity describes the ability of the body combating pathogens and 
other unwanted biological invaders. Mammalian immunity can be classified into two 
main arms: innate immunity and adaptive immunity. Innate immunity is evolutionally 
conserved, preexists and mediates immediate responses to invading pathogens, 
regardless of antigen specificity. By contrast, adaptive immunity, evolved exclusively 
in vertebrates, is generated by the somatic recombination of germ line-encoded genes, 
priming and responding to pathogens in antigen specific ways. Innate and adaptive 
immunity were thought as operating separately in the past, but it is now apparent that 
innate and adaptive immunity cooperate with each other to maximally control 
microbial infections. Innate immunity is known to initiate, shape and influence the 
effectiveness of adaptive immunity, whereas adaptive immunity can facilitate innate 
cells to better clear the invading pathogens. 
Innate Immunity 
        Innate immunity stands as the first line of defense against pathogen invasion. 
The major functions of innate immunity are (i) to mount immediate responses to 
detrimental microorganisms, either to limit the replication, colonization of pathogens 
in situ or alert neighbor cells to enter the anti-microbial states while the adaptive 




the conditions for inducing the most effective adaptive immune responses against the 
encountered pathogens. Overall, innate immunity is composed of a complicated range 
of organs, tissues, cells and molecules, such as poloarized epithelium formed 
physiological barriers, constitutively secreted mucus and anti-microbial molecules 
such as defensins, complement proteins, lysozymes and acute phase proteins, the 
release of reactive oxygen species and lytic granules, phagocytes underlying the 
epithelium, and nature killer cells infiltrated from the circulation. 
 
        Phagocytes such as macrophages and dendritic cells can recognize microbe 
directly through pathogen-associated molecular patterns (PAMPs) by pattern 
recognition receptors (PRR) (1). Pathogen associated molecular patterns are 
conserved molecular signatures among microbes of a given class, which are not 
produced by host (2). This lays the foundation for host innate immune system to 
distinguish self from invading microbes (2, 3). The best known examples of PRRs are 
Toll-like receptors (TLRs), which was first discovered in the Drosophila model in 
which a mutation of a receptor called “Toll” increased susceptible to fungal infection 
due to deficiencies in the induction of anti-fungi peptides (4). Subsequently, the 
human homologue of Drosophila Toll protein, human TLR4, was cloned and 
demonstrated to induce the production of inflammatory cytokines as well as the expression of 
co-stimulatory molecules (5). To date, a wide variety of PRRs has been identified and 
characterized: in human, 10 different TLRs have been found, and mouse has 12 of TLRs (6). 
TLRs are expressed either on the cell surface (TLR2, 4. and 5) or in endosomes/lysosomes 
(TLR3, 7 and 9), recognizing a wide range of PAMPs including lipid, lipoproteins, 




Upon recognition of those PAMPS, TLRs will trigger signal cascades, inducing anti-
microbial activities and inflammation (7). 
 
         Besides TLRs, another two groups of microbial detection system recently have 
emerged: retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs) and 
nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs). RLRs are 
RNA helicase family receptors, specializing in the recognition of viral RNA 
replicating-intermediates in the cytoplasm and inducing the production of anti-viral 
type I interferons (8). In the RLR family, three receptors have been found: RIG-I, 
melanoma differentiation associated gene 5 (MDA5) and laboratory of genetics and 
physiology 2 (LGP2) (8, 9). It has been proposed that RIG-I is involved in the 
recognition of single stranded RNA (ssRNA) virus, such as influenza A virus, VSV, 
Japanese encephalitis virus and paramyxoviruses. RIG-I was found to specifically 
recognize ssRNA containing 5’-triphosphate moiety. Some ssRNA viruses, such as 
influenza and VSV, bear such unique structure in their genomes (9, 10). By contrast, 
host self RNA does not have such a moiety: 5’-triphosphate is either removed or 
masked by a cap structure. This is another example of discriminating between self 
and nonself  employed by host innate immune system (8). MDA5 was demonstrated 
to mainly recognize double stranded RNAs either directly from virus or replicating 
intermediates of viral genomes. It has beem reported that MDA5 was required for the 
recognition of picornaviruses and Poly I:C (11). LGP2 has been suggested to serve as 





        The NLR family senses the presence of PAMPs and endogenous “danger 
signals” within cells (13). NLRs are composed of three domains: N-terminal protein 
interaction domain, a central nucleotide-binding domain and a C-terminal Leucine-
Rich Repeat (LRR)(14, 15). NLRs comprise of a large family of cytosolic PRRs, thus 
far at least 23 human and 34 murine NLRs have been found (8, 16). Some of them 
have been well characterized, such as NOD1, NOD2 and NALP3 (NATCH-LRR-
PYD-Containing Protein 3) (15, 17). NOD1 and NOD2 can detect intracellular 
bacterial components, while NALP3 can be in a complex with adaptor proteins, 
including apoptosis-associated speck-like protein containing a CARD domain (ASC) 
and CARDINAL to form a multi-protein complex called “inflammasome” in response 
to PAMPs, or danger signals, such as heat-shock proteins, monouric acids and alum, 
which in turn recruits and activates caspase-1 (18-20). Caspase-1 can cleave the 
inactive pro-IL-1 and other IL-1 family cytokine precursor (IL-18 and IL-33), and 
convert them into bioactive inflammatory cytokines (18).   
 
        Innate immunity plays crucial roles in the initiation and guidance of adaptive 
immunity. Dendritic cells (DCs) serving as professional antigen presenting cells 
express a wide variety of PRRs (21-23). Innate signals activated through PRRs-
PAMPs recognition controls the activation of DCs, indicated by up-regulation of 
costimulatory molecules, CD80 and CD86 (23-25); they also modulate the antigen 
process pathway by regulating the endosomal/lysosomal microenviroment and 
promoting the translocation of MHC II-peptide complexes from endocytic vesicles to 
cell surface (26). Moreover, innate signals down-regulate CCR6 but up-regulate 




peptides to cognate naïve CD4+ and CD8+ T cells (27, 28). Upon arrival at the lymph 
nodes, DCs migrate to T cell zone and contact with T cells in the context of MHC 
molecules. In the T cell zone, DCs provide naïve T cells with two signals for their 
activation. The first signal is the peptide loaded on the MHC molecule on DCs to be 
recognized by antigen specific TCRs of T cells, while the second one is the 
costimulatory molecules like CD80 and CD86, which will activate CD28 signal 
pathway on T cells. Depending on the affinity and density of presented peptides, the 
strength of constimulation, the profiles of cytokines secreted by DCs, naïve T cells 
will differentiate into Th1, Th2, Th17 cells (29-31). Furthermore, innate signals have 
been found to promote T cell differentiation by counteracting the inhibitory effects of 
T regulatory cells (32, 33). When antigen specific naïve T cells become activated and 
differentiate into effector cells, chemokine gradients created by innate immune 
responses facilitate the recruitement of effector T cells from lymphoid tissues to the 
sites of infection (34, 35). It has also been reported that innate signals can directly 
control B cell activation and Ig isotype switch (36, 37). In addition, it was suggested 
that innate signals can influence the generation of T cell and B cell memory (34, 38).  
 
        Innate immune response is immediate at the exact site where a given pathogen is 
encountered, playing essential roles in the early control of the infections. However, it 
is relatively non-specific, recognizing only conserved molecules shared by a broad 
range of pathogens. Neither can it mount memory immunity to any particular 
pathogens. Innate immunity is highly effective, however, many microorganisms have 




another arm of immunity, adaptive immunity, is required to more effectively combat 
those pathogens. 
Adaptive Immunity 
        Vertebrates evolved to be equipped with a second line of defense to fight 
infection, collectively termed “adaptive immunity”. This immune system utilizes 
special mechanisms to recombine a few of germline-encoded genes to generate an 
extraordinary diverse repertoire of receptors on lymphocytes to specifically recognize 
almost all the forms of antigens. It is termed as adaptive or acquired immunity 
because it adapts to the initial encounter of a given pathogen. When re-encountering 
the same pathogen, it will mount a faster, stronger and more effective immune 
response. The main functions of adaptive immunity are to recognize non-self antigens 
by means of antigen presentation and generate a complex range of immune responses 
that are tailored to maximally eliminate specific pathogen or pathogen infected cells. 
The initial encounter also leaves behind a long-lasting immunological memory, in 
which each encountered pathogen is “remembered” and will be eliminated more 
quickly and efficiently when re-infection occurs. The adaptive immunity mainly 
relies on two types of lymphocytes, T lymphocytes and B lymphocytes, to perform its 
functions. 
 
        T lymphocyte precursors are generated during hematopoiesis from 
hematopoietic stem cells in the bone marrow. Subsequently, they migrate to the 
thymus, where they will develop into mature naïve T cells. Microenvironments of 




recombinases, RAG-1 and RAG-2, act to rearrange germline-encoded genes to 
produce T cell receptors (TCRs) (39). Once TCR is delivered to the cell surface, each 
T cell precursor undergoes two selective steps before maturing into naïve T cells in 
the absence of pathogen: positive selection and negative selection. Positive selection 
takes place when precursor T cells bind cortical epithelial cells expressing MHC 
Class I or Class II  plus self peptides with a high enough affinity to accquire the 
survival signal. Negative selection is driven when precursor T cells further move to 
cortico-medullary junction of the thymus and bind to bone-marrow derived APC 
(macrophages and dendritic cells) expressing MHC Class I or Class II  plus self 
peptides with too strong binding to receive an apoptosis signal. Thus, after the two-
step selection, only those T cells expressing a TCR that recognizes self peptide: MHC 
complexes with the appropriate affinity will survive while others will be deleted by 
undergoing apoptosis, leading to the formation of a TCR repertoire that is weakly 
self-reactive but is unable to be fully activated by self-ligands (40). T cells that 
survive from the two-step selection exit the thymus as mature naïve T cells, and re-
circulate between the lymph and blood until they encounter with cognate antigens 
presented on APCs in the periphery lymphoid tissues (41).  
 
        Mature T cells include αβ Τ cells, γδ  T cells and nature killer T cells (NKT). 
The majority of T cells are αβ T cells, in which their TCRs are composed of α chain 
and β chain. In γδ  T cells, the TCR is made up of one γ and one δ chain. This group 
of T cells is much less (5% of total T cells) than their αβ counterparts, but they are 




intraepithelial lymphocytes (IEL) (42, 43). NKT cells represent a special but very 
small population of T cells (about 0.2% of all peripheral blood T cells) that share 
properties of both T cells and NK cells. In αβ T cells, the TCR is highly variable 
MHC restricted and can only recognize peptide on MHC molecules of APCs. 
Conversly, in γδ T cells, the TCR is less variable, not MHC restricted and seems to be 
able to recognize whole antigen rather than peptide-MHC complexes on the cell 
surface of APCs (42, 43). NKT cells also have αβ TCR, but their TCRs are far more 
limited in diversity and can not recognize peptide-MHC complexes (44). Rather, they 
can recognize glycolipid presented by a molecule known as CD1d on APCs (45, 46).  
                                                     
        The αβ expressing T cells can be subdivided into two different subsets based on 
the expression of either CD4 or CD8 co-receptors. Naïve CD4+ T cells recognize 
exogenous peptides loaded on MHC class II on the cell surface of professional APCs 
(DC, macrophages and activated B cells) via both TCR and CD4 molecule. In order 
to be loaded up into MHC class II molecule, antigens must be internalized into 
endocytic vesicles, in which a array of proteases will cleave it into short peptides with 
different size, only those peptides containing between 8 and 25 amino acids can be 
accommodated on MHC class II molecules. Upon the assembly of peptide-MHC class 
II complex, the MHC class II molecules direct the translocation of the complexes 
from endocytic compartments into cell surface. CD8+ T cells can recognize 
endogenously produced peptide in the context of MHC class I molecules. MHC class 
I molecules are expressed on all nucleated cells. Cells infected by viruses or other 




will be marked with ubiquitin for further processing by proteasomes (47). The 
processed peptides will be retrograde transported to ER by antigen processing 
associated transporter, TAP1 and TAP2. Within ER, they will be further trimmed by 
enzymes into 8 to 10 amino acid peptides, in turn they will be loaded on MHC class I 
molecules. Once forming the complex with MHC class I, they will transverse the 
Golgi apparatus and reach the cell surface to be recognized by CD8+ T cells (48). 
Some exogenous antigens can also enter the MHC class antigen presentation 
pathway, which is termed as cross-antigen presentation (49, 50). 
 
         Activation of T cells needs two signals. The first signal is generated through the 
specific recognition of antigen, while the second signal prevents inappropriate 
response to self antigen as self antigen seldom couples with co-stimulation 
simultaneously. In the absence of costimulatory signal, T cell receptor signaling alone 
leads to immunologic anergy. The TCR is a complex of several proteins, consisting of 
TCR alpha and beta (TCRα and TCRβ) chains and CD3 proteins. CD3 proteins are 
composed of CD3εγ and CD3εδ heterodimers and most important, a CD3ζ 
homodimer, which has a total of six immunostimulatory activated motifs (ITAM). 
Upon the interaction between TCR and peptide:MHC complexes and the formation of 
immunological synapases, the ITAM motifs on the CD3ζ are phosphorylated by Lck 
and in turn recruit ZAP-70. Lck and/or ZAP-70 can phosphorylate the tyrosines on 
many molecules, including CD28, LAT and SLP-76, which allows the formation of 
signalling complexes. Phosphorylated LAT recruits SLP-76 to the membrane, where 




on PI(4,5)P2 on the inner leaflet of the membrane to create the active intermediaries 
diacylglycerol (DAG), inositol-1,4,5-trisphosphate (IP3), and phosphatidylinositol-
3,4,5-trisphosphate (PIP3). DAG binds and activates some protein kinase C, most 
important, PKCθ in T cells, leading to a process important for activating the 
transcription factors NF-κB and AP-1 (51). IP3 is released from the membrane by 
PLCγ and activates receptors on the ER, which triggers the release of calcium. The 
released calcium then activates calcineurin, and calcineurin activates NFAT, which 
then translocates to the nucleus (51). NFAT is a transcription factor, which activates 
the transcription of a pleiotropic set of genes, most notably, IL-2, a cytokine that 
promotes long-term proliferation of activated T cells (52). Although subtle difference 
may exist, CD4+ and CD8+ T cells share the majority of properties of the activation 
pathways (51). 
 
        Once activated, naïve CD4+ T cells proliferate and differentiate into various 
“help” effector T cell subsets (Th1, Th2, Th17 and Tfh) depending on the signals 
received and cytokine microenvironment (30, 31). Traditionally, Th1 cells are 
thought to orchestrate cell-mediated immunity, involved in activating cytotoxic CD8+ 
T cells, macrophages and NK cells against intracellular pathogen infection, Th2 cells 
regulate the development of humoral immunity and are important in the clearance of 
extracellular pathogens. T “Helper” effector cells perform their effector function 
mainly through secreting different groups of cytokines. The hallmark cytokines for 
Th1 cells are IFNγ and TNFα, while IL-4 and IL-13 are the major cytokines secreted 




regulating the reactive oxygen species (ROS) and inductible nitric oxide 
synthase(iNOS), leading to more efficiently killing intracellular pathogens (53), IFNγ 
can also prime macrophage mediated antigen presentation/cross-antigen presentation 
by up-regulating MHC class molecules and other molecules involved in antigen 
presentation, such as invariant chain (54), IFNγ can induce an anti-viral state by 
inducing a wide array of anti-viral genes, most notably, Protein Kinase R (PKR)  
(53), IFNγ orchestrates leukocyte recruiment to sites of infection and enhances NK 
cell activity and B cell functions, such as Ig production and class switch (53, 54). 
Recently, certain subsets of Th1 cells have found to act direct cytolytic functions, 
which are previously considered as unique effects of CD8+ T cells and NK cells (55-
57). Th17 cells are newly characterized effector CD4+ T cells, which are associated 
with inflammation and also play roles in host defense against pathogens (58). The 
recently identified follicular T helper cells (Tfh) are specialized in facilitating B cell 
functions, such as affinity maturation, class switch, germinal center formation and the 
generation of long-lived memory B cells and plasma cells (30).  
 
        Upon activation, CD8+ T cells differentiate into cytotoxic T cells (also known as 
Tc or CTL). When exposed peptides in the context of MHC class I molecules, TC 
cells can secret the cytotoxins, perforins and the caspase activating granzymes. 
Perforins are known to form pores in plasma membrane of target cells.Granzymes can 
get entry into the target cell through the existing pores made by perforin, which in 
turn activate the caspase cascade, eventually lead to apoptosis (programmed cell 




membrane protein FAS ligand (FasL), which can bind to its receptor, Fas protein 
expressed on the target cell (59), leading to the apoptosis of target cells. Activated 
CD8+ T cells can also secrete a variety of cytokines, like IFNγ, TNFα and IL-2 etc, 
which has anti-viral and tumor functions (61, 62). 
 
        B cells represent another subset of lymphocytes in adaptive immunity, which 
play essential roles in humoral immunity. Unlike T cells, which mature and undergo 
positive and negative selection in the thymus, B cells development mainly occurs in 
bone marrow. B cell development needs several successive stages, from Pro-B cell, to 
Pre-B cell and immature B cells, and finally mature B cell, with each stage different 
in the antibody loci (63). Distinct from TCR, B cell receptor (BCR) is composed of 
membrane immunoglobulin (mIg) that contains two identical light (L) and heavy (H) 
chains with the 'V' (Variable) region and the 'C' (Constant) region. In the heavy-chain 
'V' region, there are three segments: V, D and J. These segments recombine 
randomly, in a process called VDJ recombination, to produce a unique variable 
domain in the immunoglobulin of each individual B cell. Similar rearrangements 
occur in light-chain 'V' region except there are only two segments involved: V and J 
(39). When becoming mature, B cells exit bone marrow and migrate to peripheral 
lymphoid tissues.  
 
        B cells use BCR to detect antigens. BCR, representing the surface-expressed 
immunoglobulins, recognizes unprocessed soluble or membrane-bound proteins and 




MHC molecules. When encountering its cognate antigen, B cell can use its receptor 
to internalize antigen; within B cells, internalized antigen can be processed and 
presented to CD4+ T helper cells. In most cases, the signal from antigen stimulation 
alone is not enough but needs to couple with the second signal from activated T 
helper cells for complete activation of B cells to start class switching and produce 
high affinity antibodies. Most antigens are T cell dependent, meaning that the second 
signal (co-stimulation) from helper T cells is required for maximal antibody 
production (64).  Co-stimulation includes, but  is not limited to, CD40-CD40L 
interaction between B cells and T cells, cytokines secreted from activated T helper 
cells, like IL-2 (64). Recently, a new subset of helper T cells, termed as follicular T 
help cells (Tfh) has been identified to specialize in helping B cells to be activated and 
differentiate into high affinity antibody producing cells in the germinal center. Most 
notably, those T helper cells can mediate the somatic hypermutation of the variable 
regions of immunoglobulin genes. This process will result in the increase of affinity 
of the BCR to its cognate antigen (65). Furthermore, only the population of B cells 
with BCRs of high affinity for a given antigen can be selected to survive and further 
differentiate into high affinity antibody producing plasma cells or memory B cells 
(66). Another type of antigens are called “T cell independent antigen”, representing 
that they can induce B cells to produce antibodies independent of T cell help. For 
example, many bacteria have repeating carbohydrate epitopes that directly stimulate 
B cells by cross-linking the IgM antigen receptors in the B cell, resulting in IgM 





        Upon activation and class switching, B cells differentiate into effector B cells, 
termed plasma cells. Plasma cells are terminally differentiated cells, specializing in 
producing antibodies. They are distinct from their precursors of many aspects: they 
cannot switch antibody classes, cannot act as antigen-presenting cells because they no 
longer display MHC-II, and they do not take up antigen because they no longer 
display significant quantities of immunoglobulin on the cell surface; they express 
relatively few surface antigens, and do not express common pan-B cell markers, such 
as CD19 and CD20 (68); they mainly reside in bone marrow with a long life span, 
some can even live all the life-long (69, 70). Four of structurally and functionally 
distinct antibodies are produced by plasma cells: IgG, IgE, IgM and IgA, but each 
individual plasma cell can only produce a single type. Those antibodies are essential 
players in mediating humoral immunity with broad diversity and magnitude.  
 
Immune Memory 
        Upon the first encounter with a pathogen, lymphocytes generally undergo three 
distinct phases: (1) during the effector phase, lymphocyte precursors dramatically 
divide, expand and acquire effector functions, migrate to sites of infection and act on 
pathogen clearance; (2) during the contraction phase, companying with the resolution 
of infection, most effector cells die by apoptosis, leaving behind 5%-10% of the 
initial burst pool as memory lymphocytes; (3) during the phase of memory 
maintenance, memory lymphocytes are maintained as homeostasis for long years. 
Immune memory is the cardinal feature of adaptive immunity. The antigen-




counterparts and have a decreased threshold for re-activation. Thus, when re-exposure 
to the same pathogen, it will induce an accelerated, more robust immune responses, 
leading to either entirely preventing from infection, or more efficient clearance of 
infection or dramatically decrease the severity of clinical diseases; such unique 
character of memory immune responses lays the fundamental basis for vaccination.  
 
        Both humoral and cellular immune responses are equipped with the important 
capacity of generating immunological memory, and have evolved to perform 
fundamentally distinct effector functions. The humoral memory is composed of 
memory B cells and long-lived plasma cells, while cellular immune memory include 
long-lived central CD4+  T cell memory and short-lived effector CD4+ T cell memory, 
and CD8+ T cell central and effector memory. Although T cells and B cells contribute 
to protective immunity from the re-infection through fundamentally distinct effector 
functions, their memory constitutes share many similar characteristics. These include 
but not limited to the generation of memory pools from activated precursors, 
heterogeneity in function, anatomical location and phenotype. 
 
        Memory B cells (MBCs) and long lived plasma cells (LLPCs) constitute of 
humoral immunological memory. MBCs are primarily located in secondary lymphoid 
organs, display higher frequencies in comparison with naïve B cells; they can not 
actively produce antibodies but express higher affinity BCRs (71). They respond to 
re-infection by rapidly dividing and differentiating into antibody-secreting cells, 




mainly in the bone marrow; LLPCs are terminally differentiated cells, constitutively 
producing antibodies in the absence of antigen stimulation (69). Following initial 
contact with antigens, naïve B cells proliferated at marginal zone of lymph node. 
Then, activated  B cells either retain in the marginal zone and differentiate into short-
lived plasma cells (mainly producing IgM), or enter the B-cell follicles, subsequently 
CD4+ T-cell help (most likely, Tfh cells) coordinated follicular B cells to initiate a 
germinal center (GC) reaction (72). In the GC, activated B cells undergo somatic 
hypermutation, affinity maturation and selection, eventually resulting in the 
generation of high affinity MBCs and LLPCs. In the absence of CD4+ helper T cells, 
or without CD40, CD28 or inducible costimulatory signals from Th cells, humoral 
immune responses are highly impaired and fail to generate GCs, MBCs and LLPCs 
(73, 74). CD40 signal and transcriptional factor PAX5 favor activated B cells 
differentiated into MBCs (75). Conversely, transcriptional factors Blimp-1, XBP-1 
can drive activated B cells to differentiate into LLPCs (76, 77). However, the exact 
programs governing both distinct differentiations are still poorly understood. Both 
MBCs and LLPCs can be maintained for a long time even in the absence of antigen 
(78). But factors that influence the homeostasis of MBCs remain largely unknown. 
Bone marrow niches are thought to provide LLPCs with survival signals, such as the 
bone marrow stromal cell-derived IL-6 and VLA-4 (79). In human, MBCs can 
maintain for decades and PPLCs are believed to be sustained for life long (80, 81).  
 
        Memory T cells (both CD4+ and CD8+) include two different cell types: effector 




lymphoid tissues, expressing lymphoid tissue homing chemokine receptor CCR7 and 
CD62L; TCM exhibit stem cell like qualities of self-renewal and respond to antigen by 
rapidly dividing and differentiating into effector cells; In contrast, TEM (CCR7-
CD62L-) mainly reside at peripheral tissues and mount the immediate effector 
response when re-infection occurs (83). Thus, both TEM cells and TCM cells play 
essential roles in the protective immunity depending on the nature and route of 
infection. The conventional model of memory T cell differentiation is the linear 
differentiation model, which was proposed that memory cells are derived directly 
from effector cells (84-86) . However, the differentiation pathway of memory CD4+ T 
cell is still controversial. Similar to MBCs, memory T cells can maintain their 
numbers in the absence of antigen stimulation by way of homeostatic proliferation. 
Furthermor, cytokines, like IL-7, IL-21 and IL-15, are demonstrated to be involved in 
this process (87-89).  
 
Immunoglobulins and Their Receptors 
Overview 
        Immunoglobulins are the key mediators of humoral immune responses. Immunoglobulin 
possesses a wide variety of effector functions in anti-infection immunity as followings: (1) 
stand as the first line of defense against infection by neutralize invading pathogens; (2) fix 
particulate antigen and activate complement cascades; (3) opsonize microorganisms to 
facilitate the phagocytosis by phagocytes; (4) flag-pathogen infected cells for NK cell 
mediated ADCC activity; (5) enhance the antigen presentation of invading pathogens on 




and high affinity binding to antigen and immunoglobulin Fc receptors expressed on the 
effector cells. In total, there are five isotypes of immunoglobulins in mammals: IgM, IgD, 
IgG, IgA and IgE. IgM and IgD, serving as B cell receptor (BCR), are expressed on the 
surface of naive B cells  and play essential roles in the activation of B cells. Pentameic IgM 
is also the earliest antibody to be secreted upon infection or vaccination. The secreted form of 
IgD is very unusual in the serum in contrast to other isotypes. IgG is the predominant 
immunoglobulin in serum, lymphatic fluid, peritoneal fluid and cerebrospinal fluid. It 
accounts for 75% of total serum immunoglobulin (over 30 mg/kg/d). Most notably, IgG is the 
only immunoglobulin that can pass through the human placenta to provide protection to the 
fetus. The majority of synthesized IgA are secreted to bath the vast area of mucosal surfaces. 
IgE is present in serum at the lowest concentration among all isotypes of immunoglobulin. It 
plays a vital role in the clearance of parasites, while also resulting in the unfortunate 
consequence of allergy.  
  
        Immunoglobulin exerts the maximal effector functions primarily depending on Fc 
receptors expressed on leukocytes or epithelial cells. The Fc receptors expressed on 
phagocytes such as neutrophils and macrophages can facilitate the phagocytosis of antibody 
opsonized pathogens and activat the maturation of phagosomes to destroy phagoctyosed 
pathogens (90); Fc receptors on NK cells can mediate ADCC to induce apoptosis of infected 
cells (90, 91); Fc receptors on B cells can regulate antibody responses (92); Fc receptors 
expressed on polarized epithelial cells can mediate the transport of certain isotype of 





        Polymeric immunoglobulin receptor (pIgR) is the receptor for both IgM and IgA, 
responsible for the trans-cellular delivery of IgM and IgA to the mucosal surfaces. The 
secreted IgA (sIgA) has been known as the predominant immunoglobulin in the mucosal 
secretion. The sIgA is produced by plasma cells residing in the lamina propria as dimmers 
associated with a 15-kDa J chain. Dimeric IgA (dIgA) binds to pIgR expressed on the 
basolateral domain of poloarized epithelial cells, and the IgA-pIgR complex is shuttled from 
basolateral to apical surfaces, where proteolytic enzymes cleave the pIgR to release sIgA to 
the lumen (94). Once in the secretions of the lumen, IgA can bind to pathogen particles, 
inhibiting their attachment with susceptible epithelial cells, thus blocking subsequent 
infections (95, 96). In addition to neutralizing viruses in the lumen, it has been proposed that 
IgA can also neutralize viruses within epithelial cells during its transcytotic pathway (97, 98). 
Moreover, it has been reported that pIgR can move IgA-virus complexes from basolateral 
surface to apical lumen to attenuate the viral infection in the lamina propria (99). Besides 
pIgR, there is another receptor, known as Fcα receptor (FcαR, CD89) for IgA. FcαR is 
expressed on the cell surface of neutrophils, monocytes, and eosinophils, which can mediate 
the phagoctosis and release of inflammatory cytokines upon interacting with IgA-opsonized 
targets (93, 100). 
         
        There are two receptors for IgE, the high-affinity Fcε receptor I (FcεRI) and the low -
affinity FcεRII (CD23). The high-affinity receptor FcεRI is a member of the immunoglobulin 
superfamily (it has two Ig-like domains), composed of one α chain associated with one β 
chain and two γ chains. FcεRI exhibit extremely high affinity to IgE (Kd~10-10 M), resulting 




expressed on epidermal Langerhans cells, eosinophils, mast cells and basophils (102). When 
cross-linking of IgE that is pre-bound to FcεRI by cognate antigen, mast cells or basophils 
are activated that is triggered by ITAM on the C-terminal of β chain and γ chain of FcεRI, 
resulting the degranulation and ensuing immediate hypersensitivity reactions (101, 102). 
FcεRI can also be found on antigen-presenting cells (DCs and Macrophages), and is believed 
to mediate the production of inflammatory cytokines (101). The low-affinity receptor FcεRII 
(CD23) is indeed a C-type lectin. It exists in two isoforms: CD23a and CD23b (101). They 
are widely expressed by monocytes, macrophages, dendritic cells, mast cells, eosinophils, 
epithelial cells and B cells. FcεRII has multiple functions as a membrane-bound or soluble 
receptor; it controls B cell growth and differentiation and blocks IgE-binding of eosinophils, 
monocytes, and basophils (103). 
 
IgG and Fcγ Receptors 
        Immunoglobulin G (IgG) is known as the Ig isotype with the highest 
concentration and longest half-life in the serum. IgG has four different subtypes: 
IgG1, IgG2, IgG3 and IgG4 in humans (IgG1, IgG2a, Ig2b and IgG3 in mice). Those 
distinct subtypes are not produced randomly, but depending on the milieu in which B 
cells are activated and differentiated. For example, in mice, Th1 immune responses 
are believed to induce B cell producing IgG2a or IgG3, while Th2 immune responses 
mainly induce the production of IgG1.The different subtypes differ from each other 
with different structures, including the length and flexibility of the hinge region and 




properties between Ig subtype and their receptors, IgG Fcγ receptors (FcγR), which 
determines the outcomes of IgG mediated immunity (Table I.I).  
 
        FcγRs belongs to the immunoglobulin superfamily. To date, four different 
FcγRs, FcγRI, FcγRIIB, FcγRIII and FcγRIV, have been found in mice. More 
complicated, several orthologous proteins in humans have also been identified, 
known as FcγRI, FcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA, FcγRIIIB (104). The FcγRs 
can be distinguished from each other by the affinity for the ligands, the membrane 
adaptor proteins they are associated and the signaling pathways they induce. FcγRI 
(CD64) is composed of a ligand-binding chain associated with the homodimer of a 
signal-transducing-γ chain. Within the extracellular region of the FcγRI α chain, three 
Ig-like domains exist while other FcγRs only have two such domains (90). This 
unique characteristic makes FcγRI as the only high affinity FcR with Kd~10-9M, 
allowing it bind to monomeric IgG molecule (104). FcγRI is an active receptor, 
widely expressed on innate effector cells, such as monocytes, macrophages, dendritic  
cells and neutrophils. Upon cross-linking by antigen, the ITAMs on the γ chain of 
FcγRs are phosporylatad by Src kinase family, resulting in the recruitment of SYK-
family, followed by the activation of various downstream molecules, finally leading 










Table I.I Characteristics of the IgG Isotypes.  
 
                                    
                              CHARACTERISTICS OF IgG 
 
                        
                   IgG1, IgG2, IgG3, IgG4 (human)             Subclasses 
                  IgG1, IgG2a, IgG2b, IgG3 (mouse) 
   
  Concentration in Sera 
 
                   
                  IgG1 > IgG2 > IgG3 > IgG4 (human) 
               
 




  High affinity receptor -can bind monomeric IgG 
          FcγRI: IgG3, IgG1 >IgG4>>IgG2 (human) 
                       IgG2a>IgG2b, IgG3>>IgG1 (mouse) 
 
Low affinity receptors –bind IgG-immune complexes 
                      FcγRII: IgG1, IgG2, IgG3 (human) 
                      FcγRIII:IgG1, IgG3 (human) 
            FcγRIV:IgG2a, IgG2b >> IgG1, IgG3 (mouse) 
 
           
                            
                 IgG4>IgG1>IgG3>IgG2 (human) 
 
                 IgG2a>IgG1>IgG2c>IgG2b (rat) 
 
                 IgG2a>IgG1>IgG3>IgG2b (mouse) 
           FcRn Binding 
              
                   
                            Th1: IgG1, IgG3 (human) 
                                      IgG2a (mouse) 
 
                            Th2: IgG4 (human) 
              Th Response 
 







FcγRIIb (CD32) is an inhibitory and low-affinity receptor, which contains an ITIM 
motif within its cytosolic domain. Unlike FcγRI, FcγRIIb only has the ligand-binding 
a chain. When stimulated with IgG immune-complex, the ITIM motifs of FcγRIIb are 
phosphorylated, followed by the recruitment of phosphotase SHIP-1 and SHP-1, 
leading to the inhibition of FcR signalings (107). In B cells (only expressesing the 
inhibitory FcγR), FcγRIIB has been reported to be involved in the inhibiting B cell 
activation, inducing B cell apoptosis and regulating plasma-cell survival (103). Like 
FcγRI, all other low-affinity FcγRs (Kd ~10-6M) are activating receptors; they share 
very similar signaling pathways either through the ITAMs on α chain of its own 
(FcγRIIA and FcγRIIC in human) or through associated with signal-transducing γ 
chain (FcγRIII in mice and FcγRIIIA in human) after receptor cross-linking by 
immune complexes. Those receptors are differentially involved in a variety of cellular 
functions, including, but not limited to phagocytosis, endocytosis and antigen 
presentation of immune complexes on different types of cells. Notably, FcγRIIIA 
(FcγRIII in mice) are exclusive FcγRs expressed by NK cells, mediating the potent 
antibody-dependent cytotoxicity (ADCC) reactions, leading to the killing of antibody 
marked infected cells by apoptosis (104, 108). 
 
The Neonatal Fc Receptor, FcRn 
 
        For decades, it has been known that IgG predominates in the serum and maternal 
IgG can be transported to immune-incompetent fetus or newborns. Over 45 years ago, 




bind and recycle pinocytosed IgG back into the serum (109); In addition, they 
proposed that these receptors were involved in the transmission of maternal IgG to 
fetus or newborns. The putative receptors were believed to be saturable, so that any 
receptor un-bound IgG following pinocytosis were destined for degradation (109). 
This hypothesis was put forward in the absence of any knowledge of the receptor or 
cell type. However, it explained the homeostasis of IgG in the serum. Until 1989, 
Simister and Mostov first cloned the neonatal Fc receptor (FcRn) gene from neonate 
rats (110). To date, it is widely accepted that FcRn is the corresponding receptor 
predicted by Brambell, responsible for IgG homeostasis and transcellular 
transmission.  
 
        Simister and Mostov had found that rat FcRn was a heterodimer, comprised of 
β2-microglobulin and a protein with molecular weight 45-53 kDa (110). Association 
with b2-microglobulin suggested that FcRn heavy chain might be a major 
histocompatibility complex (MHC) class I related protein because it was common to 
all MHC class I molecules. They confirmed this possibility by sequencing FcRn gene 
and then comparing with MHC class I molecule. It turned out that all three 
extracellular domains and the transmembrane domain of FcRn shared sequence 
similarity with corresponding domains of MHC class I (110). This was surprising 
because it was the first time to assign an MHC class I related molecule as an IgG 
receptor. Despite the fact that FcRn is MHC class I-like protein, the α heavy chain of 





        The X-ray crystallographic structure of the FcRn heavy chain revealed by 
Bjorkman et al further confirmed that the overall three-dimensional structure of FcRn 
resembles the structures of  molecules of MHC class I family (Figure 1.1)(112). 
However, the antigen binding groove in FcRn is rearranged, primarily due to the 
presence of proline at position 165 of the α2 domain, resulting in the occlusion of the 
peptide binding platform (112, 113). This correlates with the functional divergence 
between FcRn and MHC class I: FcRn functions as the IgG Fc receptor while MHC 
class I is involved in the antigen presentation.   
 
        To date, the genes encoding FcRn alpha chains have been isolated in many 
different mammalian species (114). It has been found that all of those FcRn 
sequences share homology (114, 115). This leads to the suggestion that mammalians 
may use the same strategy to maintain IgG homeostasis and IgG transport. Notably, 
the identification of FcRn functionally expressed in human syncytiotrophoblast 
indicated that FcRn plays a role in the placental transport of IgG from mother to fetus 
(116). More recently, Bjorkman and colleagues found that chickens employ a distinct 
receptor to transport IgY antibody across the yolk-sac membranes into the developing 
egg to confer passive immunity to the young (117); this receptor is known as FcRY, 
which is structurally unrelated to mammalian FcRn and MHC class I molecule. The 
fact of distinct receptors with similar functions in mammalians and chickens suggests 
that IgG transport by FcRn is a recent adaptation of the MHC class I family (117, 
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Figure 1.1.  The structural comparison between FcRn and MHC class I. A. the 
overall structure of FcRn and MHC I, from Burmeister et al., Nature 372, 336 - 343 






The Analysis of IgG-FcRn Interaction 
        In contrast to other FcγRs, FcRn binds to the Fc region of IgG in a strictly pH-
dependent manner (118, 119). At physiological pH7.4, FcRn can not interact with 
IgG at detectable levels, but at acidic pH condition (pH6.0-6.5), FcRn binds to IgG 
with high affinity with Kd~10-9M. FcRn does not exhibit a dramatic conformational 
change upon binding to IgG (120). The pH dependent binding between FcRn and IgG 
is indispensible of histidine residues in the CH2-CH3 interface of IgG and their 
subsequent interaction with acidic residues on the surface of FcRn (120). From the 
side of IgG, mapped by using site-directed mutagenesis, several Ile253, His310 in 
CH2 domain of IgG have been found as the key amino acids involved in the 
interaction of IgG with FcRn, but the His435 in CH3 played a more significant role in 
the mouse FcRn-IgG interaction (121, 122). Plus, the sequence -H-N-H-Y (AA 433-
436) of the CH3 domain is important for pH-dependent binding and these residues are 
found to be highly conserved across species (123, 124).  Further analyses by 
employing mutated recombinant Fc fragments demonstrated that amino acids at 
position 257 and, to a lesser extent, positions 307 and 309 in proximity to the CH2-
CH3 domain interface also play a role in the FcRn-Fc interaction. However, the role 
of residues 257, 307, and 309 is relatively less than that of Ile253, His310, and 
His435 (123, 125, 126). The amino acids of Fc region involved in the binding to 
FcRn were summarized in Table I.II. Furthermore, it has been found that fragment B 
of staphylococcal protein A shares the identical binding sites on Fc region with FcRn, 





      Crystallographic structure on the FcRn-Fc complex has revealed that the anionic 
residues Glu117, Glu132 and Asp137 on the α2-helix of FcRn form salt bridges with 
these protonated histidines of IgG at acidic pH (126). Besides, the hydrophobic Ile 
253 of IgG engages with Trp133 of FcRn; Furthermore, Ile1 of β2-microglubolin was 
also found to be involved in bind to IgG. Thus, both α2 domain of FcRn and β2-
microglubolin are crucial for the pH dependent binding of IgG (121, 126). Site-
directed mutagenesis and crystallography structure studies have suggested that the 
FcRn and FcγRs bind to Fc region of IgG at distinct sites (128, 129). The residues in 
the lower hinge region of Fc are critical for IgG binding to FcγRI, FcγRIIa and 
FcγRIII (130, 131). Other residues close to lower hinge spatially, such as Pro331 and 
Glu318 on Fc are also involved to bind to FcγRs (130, 131).The N-linked 
glycosylation of Fc region of IgG plays vital roles for FcγR binding, which is not 
necessary for FcRn binding (104, 132). Thus, unlike FcRn which bind to Fc via CH2-
CH3 region, FcγRs interact with IgG mainly through the interface between the lower 
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Met  Ile  Ser Arg Thr Pro
Met  Ile  Ser Arg Thr Pro
Met  Ile  Ser Arg Thr Pro
Met  Ile  Ser Arg Thr Pro
Thr Val  Leu His Gln 
Thr Val  Val  His Gln 
Thr Val  Leu  His Gln 
Thr Val  Leu  His Gln 
His  Asn  His  Tyr 
His  Asn  His  Tyr 
His  Asn  Arg Phe








Thr   Ile Thr Leu Thr Pro
Met  Ile  Ser Leu Thr Pro
Met  Ile  Ser Leu Thr Pro
Met  Ile  Ser Leu Thr Pro
Pro  Ile  Met  His Gln  
Pro  Ile  Gln  His Gln 
Pro  Ile  Gln  His Gln 
Pro  Ile  Gln  His Gln 
His  Asn  His His
His  Asn  His His
Lys  Asn  Tyr Tyr








Thr  Ile Thr  Leu  Thr Pro
Thr  Ile Thr  Leu  Thr Pro
Leu  Ile Ser  Gln  Asn Ala
Met  Ile Thr Leu  Thr Pro
Pro  Ile   Leu His Gln 
Pro  Ile  Val  His Arg 
Pro  Ile  Gln  His Gln 
His  Ile  Gln  His Gln 
His  Asn  His His
His  Asn  His His
His  Asn  His His
















FcRn transports IgG Accross Mucosal Barriers 
        Of the five antibody class, IgG has long been known to be the only one that is actively 
transported from mother to offspring (133-135). Later on, the FcRn was found to perform 
such unique function (110). In human, the offspring acquires maternal IgG mainly through 
placenta. FcRn expressed on placental syncytiotrophoblasts can accumulate IgG in the 
endosomes via pinocytosis (136, 137). The IgG-containing endosome is then gradually 
acidified thereby allowing IgG to bind tightly to FcRn present in this compartment. The 
vesicle then fuses with the membrane on the fetal side of the syncytiotrophoblast, where the 
physiological pH promotes the dissociation of IgG from FcRn (116, 137, 138). Nevertheless, 
neonates in rodents accquire maternal IgG via the intestine (133, 134). Maternal IgG from 
ingested milk passes through the stomach of rodent neonates, in turn maternal IgG contained 
in the slightly acidic stomach contents reaches the duodenum, where IgG is bound to FcRn 
that is most efficiently expressed by the epithelial cell lining the intestine prior to the 
weaning (122). The FcRn-IgG complexes are then internalized by receptor-mediated 
endocytosis, subsequently transcytosed across the polarized barrier, eventually release IgG at 
the lamina propria, where it is at physiological pH (122, 139). In β2-microglobulin-/- or FcRn 
-/- mice, no maternal IgG was transported (140, 141). These studies confirm that FcRn is the 
receptor involved in the transport of IgG from mother’s milk to newborns. More recently, it 
was reported that there is also a minor route for IgG transport in rodent. The successful 
cloning FcRn from rat yolk sac endoderm indicates that this Fc receptor is also involved in 
the maternal IgG transfer in rodents (142).  
         




rodent. In humans, FcRn is constitutively expressed by intestinal epithelial cells regardless of 
age and developmental stages (143, 144). The intestinal expression of FcRn in rodent is 
highest on the epithelial cells of the proximal small intestine during the neonatal period and 
declines rapidly to unappreciable level after weaning (139, 145). The intestinal expression of 
FcRn in adult human suggests additional roles in FcRn besides the maternal IgG transfer. 
One possibility is that FcRn can transport IgG from lamina propria to the intestinal lumen. 
This is the novel function for FcRn because previous evidences focused on the transport from 
the apical to basolateral direction. Subsequently, several in vitro experiments using intestinal 
and other cell lines have confirmed the possibility that FcRn can transport IgG across 
polarized epithelium bi-directionally (146-148).  
 
        To date, bi-directional transport of immunoglobulin is a unique function solely 
discovered for FcRn among all other Fc receptors, including pIgR. This suggests that FcRn 
may transport pathogen specific IgG induced by infection or vaccination to mucosal sites to 
protect host from mucosal infection. Furthermore, more recently, Blumberg and colleagues 
showed that human FcRn can transport IgG–bacteria complexes across the epithelium barrier 
by using a human transgenic mice model (149). Human FcRn in the mouse intestine was able 
to carry the immune complexes across the epithelial layer, releasing the immune complex at 
lamina-propria, which in turn was captured by DCs. DCs then efficiently processed and 
presented antigen to antigen-specific T‑cells in the draining lymph node (145, 149).  
 
FcRn Protects IgG from Degradation 




highest concentration in the serum (1-2mg/ml in mice and 10-12mg/ml in human) relative to 
all other four classes of immunoglobulin. FcRn is believed to function to maintain IgG 
homeostasis. This was proved by showing that FcRn knockout mice or β2-microglobulin 
knockout mice have significantly lower IgG levels in serum (141, 150, 151). Furthermore, 
the IgG half-life in the serum of knockout mice decreased dramatically to 1 day compared to 
6-8 days in wild type mice (141). It has been proposed that IgG of high concentration in the 
serum is pinocytosed into acidic endosomes, where FcRn will capture pinocytosed IgG from 
the serum; Subsequently, FcRn will recycle IgG back to the plasma due to the physiological 
pH condition. For those unbound IgGs, they will be destined to degradation in the lysosome 
(152). To some extent, this hypothesis has been confirmed by several findings: (1). FcRn 
resides mainly in early endosomes, rather than at cell surface (152, 153); (2). Recombinant 
IgG with FcRn binding site mutations was found mostly in lysosomes and eventually 
degraded revealed by confocal microscopy analysis (154, 155); (3). In the in vitro 
experiment, living images have been performed to track IgG salvage pathways successfully 
(156, 157). 
 
        Although FcRn is widely accepted as an IgG salvager, until recently it has been shown 
that FcRn extend the IgG half-life carrying out on both hematopietic monocytes, 
macrophages, dendritic cells as well as endothelial cells (158, 159). Despite monocytes, 
macrophages and dendritic cells have been long found to express FcRn, only recently they 
were reported to be involved in the IgG homeostasis (159). By taking advantage of irradiated 
bone-marrow chimeric mice, it was observed that bone-marrow-derived cells can protect IgG 




protection. However, its definite role in IgG salvage could not be confirmed due to the lack 
of endothelial FcRn specific knockout mice. Most recently, this issue has been addressed by 
Ward and colleagues (159). They generated endothelial FcRn knockout mice, and as 
expected, the IgG level in mice with conditional deletion of FcRn in endothelial cells was 
significantly lowered (159). Thus, endothelial cells as well as myeloid monocytes, 
macrophages and dendritic cells play vital roles in the homeostasis of IgG in the serum.  
 
        Macrophages and dendritic cells are known as professional antigen presentation cells. It 
is interesting to probe whether FcRn on those cells are involved in the antigen presentation of 
immune complex besides their role in IgG protection. Indeed, a recent report demonstrated 
that FcRn can promote the antigen presentation of immune complex on DCs to CD4+ T cells 
(160). In FcRn knockout mice, the presentation of immune complex was largely impaired 
(160). However, the underlying mechanism needs to be further investigated.  
 
         Recently, FcRn has also been reported to bind albumin and extend its half-life (161). 
Albumin is the most abundant plasma protein with long half-life in the serum, accounting for 
70% of the total serum protein. It is not unusual if a receptor is involved in the maintenance 
of such high level of serum protein. Indeed, FcRn has been proved to play such a role. In 
FcRn-deficient mice, the serum albumin concentration is reduced to 40% of the normal level 
and the half-life of albumin is shortened to 1 day from 6-8 days in the wild type mice (161). 
It is intrigueing that FcRn uses the distinct sites to bind albumin as compared to binding to 
IgG. Furthermore, FcRn binding to albumin is also pH-dependent. Therefore, FcRn can 






FcRn Trafficking to Endosomes Is Critical For FcRn Function 
        FcRn are widely expressed on a variety of cell types, including epithelial, endothelial 
and antigen presenting cells, governing IgG homeostasis and trancellular transport (118, 
153). FcRn binding to IgG exclusively occurs at acidic pH condition (119, 121). It correlates 
that FcRn mainly resides in acidic endosomes at steady state (152, 153, 155). It is logical to 
conclude that in order to perform IgG protection and transcytosis function, FcRn has to 
traffick into endosomes either directly from trans-golgi-networks (TGN) or endocytosed 
from cell membrane. Nevertheless, the mechanisms of the regulation of FcRn trafficking into 
endosomes are not fully understood. 
         
        Trafficking of transmembrane proteins to endosomes depends on sorting signals within 
the cytosolic domains of the protein (165). They are shown as short and linear sequences of 
amino acid residues. So far, several sorting signals responsible for endosomal traffic have 
been identified. One is referred to as tyrosine-based sorting signals, characterized as the 
NPXY or YXXφ consensus motifs (166, 167). These motifs are phosporylated, then 
recognized by the adaptor protein complexes, like AP-1, AP-2 and AP-3 and AP-4 (168-
170). A large array of endosomal proteins contain tyrosine based sorting signals. For 
example, LDL receptor and insulin receptor contain NPXY-type sorting signals, whereas 
LAMP1, CD63, CD1d and transferrin receptor possess YXXφ−type signals (171, 172). The 
second type of endosomal sorting signals is known as dilucine-based signal, consisting of 




be recognized by adaptor protein complexes, whereas DXXLL is in engagement  with 
another family of adaptors known as GGAs (174). A large group of endosomal proteins 
contains such sorting signals, such as LamP, LIMP II, invariant chain ([DE]XXXL[LI]) and 
CI-MPR, CD-MPR, GGA (DXXLL)(175). In addition to sorting signal peptide motifs, 
unbiquitination of the lysine residune within the cytoplasmic domain of the protein is another 
type of sorting signal (176, 177). This machinery may regulate the endocytosis of cell 
membrane protein to endosomes, like some cell surface receptors, EGF, MEF and CSF-1 
(177). Some proteins, such as MHC II, do not contain any sorting signals within their 
cytoplasmic domain, but they are able to reside in endosomes by forming the complexes with 
accessory proteins which possess sorting signals, like invariant chain which contains a 
dilucine based sorting motif (178).  
 
        Presumably, two factors may influence the endosomal trafficking of FcRn. First, the 
cytoplasmic domain of FcRn contains the putative diluencine motif-based endosomal sorting 
singal: GDDTGVLLP, which is DE]XXXL[LI] type (179). Such signal sequence is 
conserved across different species, including human, mouse, rat bovine and porcine, 
suggesting its importance in FcRn trafficking (180). Second, FcRn may also form complexes 
with partner protein, which may be involved in the regulation of FcRn trafficking. The first 
hypothesis was partially resolved by Neil and colleagues (179). They reported that both 
dilucine and tryptophan based motifs were involved in the endocytosis of FcRn, but it was 
lack of direct evidence that such signals were also responsible for the sorting of FcRn from 





Modulating the Interaction of IgG with FcRn 
        Because FcRn functions as IgG salvager and transporter, it is apparent that FcRn can be 
targeted to modulate the IgG level or improve the pharmacokinetic efficacy of therapeutic 
antibodies or deliver therapeutic agents in conjugation with Fc fragment to specific tissue or 
organs. A wide variety of autoimmune diseases are caused by excessive pathogenic self 
antibodies, such as myasthenia gravis, bullous pemphigoid, idiopathic thrombocytopenic 
purpura (ITP) and systemic lupus erythematosus (SLE). It is possible to modulate the IgG-
FcRn interaction to decrease the pathogenic antibody level. Several attempts have been made 
to test this hypothesis. The first method is to administer excessive innocuous IgG. The high 
dosage of exogenous IgG will compete with endogenous pathogenic IgG, leading to the 
saturation of FcRn by exogenous IgG. As a result, endogenous pathogenic IgG will drop off 
from FcRn and destine to degradation in the lysosome. In humans, high dosage of 
intravenous immunogloblulin (IVIG) has been approved for clinical use in treating 
autoimmune diseases (181). In mouse models, IVIG treatment has been shown to decrease 
pathogenic antibody levels and can interfere with the interaction between FcRn and 
pathogenic antibody (89). Another method to attenuate the FcRn-pathogenic antibody 
interaction is to employ FcRn specific antibody. It has been recently reported that a 
monoclonal antibody specific for FcRn heavy chain has been described to alleviate the 
disease symptoms in rats with experimentally induced myasthenia gravis (182). The third 
approach is to engineer Fc mutants with increased affinity to FcRn. Administration of such 
Fc mutants will out-compete endogenous antibodies. Indeed, humanized IgG monoclonal 
antibodies with unusually high affinity to FcRn leads to the degradation of endogenous 




screened small molecules or peptide inhibitors of the FcRn-Fc interaction would be 
promising to be exploited to decrease the severity of antibody caused autoimmune diseases 
(184). 
 
Mucosal Barriers and Potential Roles of FcRn In mucosal Immunity 
 
The Organization of Mucosal Barrier 
        Mucosal epithelia, such as in the gastrointestinal, respiratory, and genitourinary 
tracts, form an interface between the external environment and the internal milieu of 
the body. The polarized epithelial cells, lining these mucosal cavities contains 
stratified and single cell layers (94, 185). They have two separate plasma membrane 
domains, apical and basolateral, which are separated by tight junctions. These 
domains further form barriers that allow for the selective exchange of 
macromolecules between the lumen and submucosal tissue under physiological 
conditions. Specifically, the transcellular pathway involves endoctyic uptake of 
macromolecules, generally by the receptor mediated and/or fluid-phase endoctytosis, 
at the apical or basolateral membrane. These molecules are then transported through 
the cell in endoctyic vesicles to the opposite membrane surface where they are 
released into the extracellular space. Therefore, the transcellular pathway is a major 
route in moving soluble macromolecules across the mucosal epithelial barrier. 
Besides transcellular pathway of macromolecular transport, in intestinal mucosa and 
possibly in respiratory mucosa, microfold or M cells, which are localized over 




particulate antigens across their cytosol to the underlying lymphoid follicles (186). 
However, M cell mediated macromolecular transport through polarized epithelial 
monolayer is technically very limited, because M cells are sparsely scattered. 
Furthermore, the population of M cells is very rare, accounting for 0.1% of epithelial 
cells (187).  
 
        The mucosal surfaces can be divided into two types according to their primary 
role and anatomical features. Type I mucosal surfaces represent those of the intestine, 
lung, and uterus, and they are covered by a simple monolayer epithelium that serves 
physiological functions, such as absorption and respiration. Type II mucosal surfaces 
include those of the oral, esophagus and vaginal cavities, and they are covered by 
stratified squamous epithelia. The main function of type II mucosa is to provide 
physical protective barriers for the host species. For both type I and II mucosa, in 
order to perform their vitally physiological functions, such as absorption, respiration 
and reproduction, the host is inevitably exposed to environmental pathogens, 
including a variety of viruses. To counteract with such detrimental environment, the 
body has evolved delicate mucosal immune system, containing most of the body’s 
lymphocytes (188). Anatomically the lymphocyte populations are divided into those 
present in epithelium (intraepithelial lymphocytes, IELs) and those in the underlying 
lamina propria (lamina propria lymphocytes, LPLs) (42, 189). The LPLs can be 
subdivided into those from inductive sites (organized lymphoid nodules) and those 
from effector sites (diffuse lamina propria) (185). Only type I mucosal surfaces 




tissue (MALT) (190). The small intestine contains peyer’s patches (PPs) and isolated 
lymphoid follicles (ILFs). The large intestine contains ILF and the appendix, and the 
nasal mucosa harbors the nasopharynx-associated lymphoid tissue (NALT). These 
MALTs occur directly beneath the mucosal epithelial cells and hence do not possess 
afferent lymphatics. These MALTs consist largely of B cell forming follicular 
structures interspersed by interfollicular regions in which the majority of T cells 
reside. Distinct DCs are also found in the follicles, IFRs, intraepithelial and lamina 
propria region, playing central roles in the recognition and presentation of antigens to 
T cells (191, 192).In contrast, type II mucosal surfaces do not possess MALT directly 
underneath the epithelial layer under steady-state conditions. However, both type I 
and II mucosal lamina propria constituents can be drained by locally mucosa-draining 
lymph nodes(190). For example, cervical lymph nodes (CLN) drain the oral and 
nasopharyngeal mucosa, mesenteric lymph nodes (MLN) can accumulate DCs from 
the LP and PP, bronchial /mediastinal lymph nodes can drain the respiratory epithelial 
mucosa, and iliac/inguinal lymph node drains the reproduction tract (190) .  
 
Viral Infection at Mucosal Sites 
        In general, the mucosal surfaces are the primary sites for microorganism entry 
and infection due to their vast area and underlying various types of susceptible cells. 
In terms of viral infection, some viruses, for example influenza virus and rotavirus, 
are limited to the mucosa; in many other viruses, such as polio, measles and HIV, 
crosses the epithelial barrier to spread to other organs distal of initial entry. Since 




membrane, the polarized distribution of host cellular receptors determines whether a 
virus initiates infection at apical or basolateral side. For example, the entry of 
vesicular stomatitis virus (VSV) and reovirus is restricted to the basolateral surfaces, 
whereas SV40 and rotavirus infections only occur following attachment to the apical 
surfaces. However, influenza virus can initiate infection at both apical and basolateral 
domains, although the apical domain is preferred. In addition, the budding of progeny 
virus particles also occurs in a polarized fashion, for example, VSV budding occurs 
primarily from the basolateral surface, and sendai viruses released exclusively from 
the apical surface. Besides epithelial cells, marcrophages, dendritic cells, T and B 
lymphocytes underlying or within epithelium are also permissive for some viruses. 
For example, most T lymphocytes underlying mucosa are CD4+ and CCR5+, HIV 
can establish local infection immediately after crossing the epithelium by using these 
two receptors, subsequently effectively spread for systemic infection (98).   
 
Immunoglobulins in the Mucosal Secretion 
        In comparison with other immunoglobulin, secretory IgA (sIgA) has been long 
considered as playing predominant role against viral infection at mucosal surfaces. 
sIgA is produced by plasma cells residing in the lamina propria as dimmers 
associated with a 15-kDa J chain. Dimeric IgA (dIgA) binds to the polymeric 
immunoglobulin receptor (pIgR) on the basolateral domain, and the IgA-pIgR 
complex is shuttled from basolateral to apical surfaces of polarized epithelium, where 
proteolytic enzymes cleave the pIgR to release sIgA to the lumen (94). Once in the 




attachment to or fusion with susceptible epithelial cells, thus blocking subsequent 
infections (95, 96). To further define the defensive roles of IgA against mucosal viral 
infection, J chain, IgA and pIgR deficient mice were generated to be challenged with 
common mucosal viruses, such as influenza, rotavirus and herpes simplex virus. 
Unexpectedly, results suggested that sIgA was not necessarily required for the 
protection of viral infection at mucosal surfaces (193, 194). For example, the IgA 
knock out mice exhibit comparable level of influenza infection as IgA+/+ littermates 
(193, 195). Furthermore, passively transfer of viral specific neutralization IgA, 
specific for influenza HA, could not block corresponding viral infection at mucosal 
surfaces, but passively IgG could (196). Taken together, those investigations 
suggested that besides IgA, other Ig isotypes, particularly IgG, are also involved in 
mucosal immunity.  
 
        IgG has frequently been detected in secretions of human mucosal surfaces, such 
as the oral mucosa, small and large intestine, lung, and genitourinary tract (Tabel 
I.III). IgG predominates or exhibits comparable level as IgA in certain human 
secretions (197-200). Furthermore, IgG and IgA antibodies are equally effective in 
preventing mucosal infections (201, 202). Several studies have demonstrated the 
importance of IgG in the clearance of or prevention of infections at mucosal surfaces 
(196, 203).The passive administration of rhesus macaques with a mixture of anti-HIV 
neutralizing IgG prevented the transmission of the virus (204, 205). For influenza 
infection, it has been reported that passive transfer IgG, rather than IgA can cure 









Fluids IgA IgG 
Nasal 70-864 8-304 
Bronchoalveolar 3 13 
Milk 470-1632 40-168 
Duodenal 313 104 
























FcRn Mediated IgG Transport at Mucosal Surfaces 
        In contrast to pIgR-mediated dIgA transport, little is known about how IgG 
presents at mucosal surfaces. For decades, the mucosal IgG was considered to 
transude from the serum, or intestinal IgG from bile. However, it has been found that 
under some conditions, the isotype pattern and concentrations of IgG in mucosal 
secretions are distinct from those of serum, ruling out the transudation of serum 
antibody (207). In addition, mucosal IgG derived from locally plasma cells in lamina 
propria has been extensively detected (207, 208). All those data suggest that an active 
transport system may be responsible for the appearance of IgG in mucosal secretions. 
As discussed previously, FcRn is constitutively expressed by mucosal epithelial cells, 
mediating bi-directional transepithelial transport of IgG. Therefore, it is rational to 
presume that IgG shown at the mucosal sites is dependent of FcRn. Indeed, our 
unpublished data have shown that intra-peritoneal administration of biotin-labeled 
IgG can be detected at both respiratory mucosal lavage and vagina fluid solely in wild 
type mice, but not in FcRn knockout mice. However, the further investigations need 
to be done in the context of infection or vaccination.   
 
Mucosal Vaccine Development 
        Mucosal surfaces of respiratory, gastrointestinal and urogenital tracts are lined 
by polarized epithelial cells. The polarized epithelial layers are distributed into apical 
and basolateral domains with distinct membrane compositions by tight junction. They 
form the first line of defense for the evasion of danger pathogens. Underneath the 




associated lymph tissues, or scatter in lamina propria, which trigger both local and 
systemic immunity against microbial infections. Due to the vast area of mucosal 
surfaces and frequent exposure to external environment when performing vital 
physiological functions, such as breathing and digestion, the mucosal tissues are the 
primary sites for microbial infections. Indeed, the majority of viruses initiate their 
entry into body at the mucosal surfaces. Some viruses can bind to cellular receptors 
expressed either on apical or basolateral surfaces of epithelium for internalization and 
subsequent replication, like influenza viruses, Sendai viruse and vesicular stomatitis 
viruses. In addition, some viruses, like human immunodeficiency viruses (HIV), can 
take advantage of the process of transcytosis of epithelial layer, then infect underlying 
lymphoid cells (98).  
 
        Vaccination is the most effective and efficient way to control viral infections. 
Despite a wide array of vaccines have been successfully developed for the prevention 
and control of systemic infections, many viruses that infect mucosal epithelial cells or 
initiate systemic infection at mucosal sites are still big challenges and lack of 
effective vaccines, such as RSV, HSV-2 and HIV (209). Pre-existing antibodies 
and/or immune memory lymphocytes at mucosal sites are required for the maximal 
protection from many pathogens that cause mucosal infection like HIV(210). In this 
regard, mucosal vaccination is more effective than parenteral vaccination which is 
assumed to poorly induce mucosal immune responses (99, 209, 211). In addition, 




comparable to systemic vaccination, which is of greater value for the control of some 
pathogens which require both systemic and mucosal immunity (210, 211).  
 
        Even though mucosal vaccination is assumed as the most effective way to 
control mucosal infection, the development of mucosal vaccines progresses slowly. 
Several challenges for mucosal vaccine development have been proposed: (1) vaccine 
components are largely diluted by mucosal secretions; (2) vaccine constitutes are 
captured in mucus gels, resulting the degradation by proteases; (3) vaccines are 
excluded by epithelial barriers, insulating from antigen presenting cells; (4) it is lack 
of effective and safe adjuvants, which can break into the mucosal immune tolerance; 
To overcome those difficulties, a lot of strategies have been employed to develop 
effective mucosal vaccines, including the administration of relatively large dosage, 
taking advantage of novel materials for effective delivery of mucosal immunogens, 
targeting M cells for efficient sampling of antigens and combining TLRs or toxin 
components in the formula to alert the mucosal immune system. In despite of those 
attempts, little progress is made in the past decades and effective and safe mucosal 
vaccines are still of great need, in particular, for the prevention and control of HIV 
infection (209). The ideal mucosal vaccine candidates should induce broad immune 
responses, including both mucosal and systemic responses, both humoral immune 
responses (serum IgG and secretion IgA) and cellular immune responses (CTL) and 
long lived memory immune responses (constitutively produced antibodies, long-lived 
plasma cells, memory T cells and B cells)(211). Apparently, much work remains to 





Specific Aims  
        FcRn are constitutively expressed by most mucosal epithelial cells, governing 
the transport of IgGs from lamina propria to lumen and vice versa, possibly playing 
unique roles in antiviral immunity. However, in order to function in the transport of 
IgG across mucosal barrier, FcRn must be first delivered into early or sorting 
endosomes. How FcRn traffick into early endosomes is incompletely known. FcRn 
has a putative dilucine motif in the cytoplasmic tail domain, which is widely believed 
to be a sorting signal well characterized in a variety of endosomal/lysosomal residing 
molecules. Besides intrinsic sorting signal, interaction protein partners, like adaptor 
proteins and chaperons, are also involved in protein trafficking, for example, MHC 
class II associated invariant chain (CD74) directs MHC II molecules into acidic 
endosomes where antigen loading to MHC II occurs (178). Although the structural 
similarity to MHC class I molecule, FcRn intracellular trafficking is more like MHC 
class II, both of which are synthesized in the endoplasmic reticulum, further modified 
in the Golgi, and sorted from TGN into endosomal compartments. Because invariant 
Chain (CD74) plays an essential role in MHC II trafficking, we reasoned that CD74 
may also interact with FcRn and regulates its intracellular trafficking. Therefore, 
specific aim 1 is to define the role of putative dilucine motif and possible CD74 
association in regulating FcRn intracellular traffic.  
 
        In contrast to pIgR mediated single way of dIgA transport, FcRn can transport 
IgG bidiretionally across polarized epithelium. To take advantage of this unique 




fused with IgG Fc across epithelial barrier into lamina propria and the circulation, 
leading to elicit both systemic and mucosal immunity against corresponding viral 
infection (Figure I.II.A). Therefore, specific aim 2 is to determine whether FcRn 
functions as vehicle of subunit vaccine to deliver Fc fused viral antigens for 

























































Figure I.II. A. FcRn can transport IgG bidirectionally across the polarized epithelial 
cells and IgG can be uptaken by FcγRs at APCs. B. Could FcRn transport Fc-fused 
viral antigens across the polarized epithelia and target it onto profession APCs to 

























Chapter 2: The MHC Class II Associate Invirant Chain Interacts 





The neonatal Fc receptor for IgG (FcRn) transfers maternal IgG to the 
offspring and protects IgG from degradation. The FcRn resides in an acidic 
intracellular compartment, allowing it to bind IgG. In this study we found the 
association of FcRn and invariant chain (Ii) by immunoprecipitation. The 
interaction was initiated within the endoplasmic reticulum by Ii binding to either the 
FcRn HC alone or FcRn HC-β2m complex and appeared to be maintained 
throughout the endocytic pathway. The CLIP in Ii was not required for FcRn-Ii 
association. The interaction was also detected in IFN−γ treated human macrophage-
like THP-1, epithelial and endothelial cells, and mouse bone marrow-derived 
dendritic cells. A truncated FcRn, without the cytoplasmic tail, was unable to traffic 
to early endosomes; however, its location in early endosome was restored by Ii 
expression. FcRn was also detected in the late endosome/lysosome only in the 
presence of Ii or upon exposure to IFN-γ. In human monocyte- or mouse bone 
marrow-derived immature dendritic cells, FcRn failed to rescue in the late 
endosome/lysosome in the absence of Ii chain. Furthermore, the cytoplasmic tail of 
Ii conferred tail-less FcRn a route to both the early endosome and late 




macrophage and dendritic cells or epithelial and endothelial cells where Ii is 
induced under inflammation and infection, these results reveal the complexity of 
FcRn trafficking in which Ii is capable of expanding the boundary of FcRn 
trafficking. Taken together, the intracellular trafficking of FcRn is regulated by its 
intrinsic sorting information and/or an interaction with Ii chain.   
 
INTRODUCTION 
         The neonatal Fc receptor for IgG (FcRn) was first identified in the intestinal 
epithelial cells of a suckling rodent, where it is expressed at high level (212). 
However, its functional expression has recently been acknowledged in a diverse 
array of cell types and tissues, including epithelial cells, endothelial cells, 
macrophages, dendritic cells, and neutrophils of humans and rodents at all ages 
(118). FcRn is composed of a heavy chain (HC, 45 kDa in humans and 50 kDa in 
rodents) nonconvalently associated with a light chainβ2m (12 kDa)(153, 212). The 
HC comprises three extracellular domains that are anchored to the cell surface by a 
single transmembrane segment and a carboxyl-terminal cytoplasmic tail. The 
association of FcRn with β2m is critical for FcRn exit to the endoplasmic reticulum 
(ER) (213). As previously reviewed in this thesis, although FcRn shares extensive 
structural homology with MHC class I, it is unable to present antigenic peptides to 
cognant T cells due to its narrowed antigen binding groove. Instead, FcRn transfers 
maternal IgG across the polarized placental and/or intestinal epithelial cells, which 
allows newborns to obtain humoral immunity against antigens encountered by the 




a transporter, FcRn protects IgG and albumin by extending their life spans. 
Consequently, this Fc receptor establishes IgG (11-12 mg/ml for human) and 
albumin (30 to 50 mg/ml for human) as the most abundant proteins in the blood. 
This character ensures that IgG generated upon antigenic exposure or infection has a 
long-term protective immunity. On the other hand, FcRn could also prolong the life 
span of pathogenic or autoimmune IgG, which links FcRn to autoimmune diseases.  
         
        FcRn binds IgG isotypes in a pH-dependent manner, binging IgG at acidic pH 
(6.0-6.5) and releases IgG at neutral or higher pH. In the majority of cell types, 
FcRn resides primarily in the early acidic endosomal vesicles with limited cell 
surface expression. In early endoosmes, FcRn catches IgG that enters cell by 
pinocytosis or endocytosis (152). Subsequently, FcRn recycles IgG back to the cell 
surface in nonpolarized cells or transcytoses IgG to the opposite surface in 
polarized epithelial cells. The near neutral pH of extracellular environment causes 
IgG release from FcRn. The IgG that does not bind to the FcRn inside cells would 
move to lysosomes where it undergoes degradation. The FcRn-IgG transport 
pathway is further elaborated by recent studies that identify early endosomes as the 
major sorting location for FcRn-IgG complex in endothelial cells (152, 156). In 
most cases, FcRn does not appear in the late endosomal/lysosomal compartment of 
either endothelial or epithelial cells. Two targeting signals, a tryptophan-and a 
dileucine-based motif in the cytoplasmic tail of FcRn has been postulated to 
mediate internalization of FcRn from the plasma membrane or transport of FcRn 




Ca2+-dependent calmodulin-binding motif in the cytoplasmic tail of FcRn in 
modulating the intracellular trafficking of FcRn was also reported (148). Despite 
these studies, it still remains uncertain about its detailed trafficking and regulation 
of its entry into the endocytic pathway under physiological and pathophysiological 
conditions.  
       
        Invariant chain (CD74, Ii) is a nonpolymorphic, type II integral membrane 
glycoprotein. Ii chains form a trimer in the ER, where, each Ii non-covalently binds 
to a MHC class II αβ heterodimer, thereby forming a nonameric complex (αβIi)3  
(214). The binding of Ii chain with MHC class II in the ER stabilizes the MHC class 
II and protect it from binding to endogenously generated peptides. When the 
nonamer reaches the trans-Golgi network (TGN), the complex is sorted away from 
the secretory pathway and routed to the endocytic pathway, ultimately to lysosome-
like compartments, called MHC class II compartments (MIIC). The N-terminal 
cytoplasmic tail of Ii chain contains two acidic dileucine-based endosomal targeting 
motifs (D/EXXXLL), which direct MHC class II to the endocytic pathway (178). 
Upon entry of the nonameric complex to endosomes, Ii chain is gradually degraded 
by pH-dependent cathepsin proteases (215). Consequently, a small fragment, called 
class II-associated invariant chain peptide (CLIP), is left in the peptide-binding 
groove of MHC class II. The removal of CLIP from MHC class II, which is 
catalyzed by HLA-DM in humans (216), facilitates the binding of antigenic 
peptides derived from internalized antigens for antigen presentation. Thus, Ii chain 




stabilizing MHC class II in the ER and directing MHC class II away from the 
default secretory pathway to endocytic pathway.          
             
        Although FcRn is structurally similar to MHC class I, its intracellular 
trafficking pathway is much more analogous to that of MHC class II. Since Ii chain 
plays such an important role in MHC class II trafficking to the endocytic pathway, 
we hypothesized that Ii molecules could play an additional role in directing FcRn 
trafficking within the endocytic compartments by physical association with FcRn. 
We were surprised to find that the Ii was indeed capable of associating with FcRn 
and regulating FcRn trafficking. Although dispensable under a certain 
circumstance, the interaction of Ii chain with FcRn offers an additional targeting 
signal that directs FcRn into the endosomal/lysosomal compartments, especially 
under immunological, inflammatory, and infectious conditions. Our results provide 
discover a novel role of Ii chain in modulating FcRn intracellular trafficking 
pathway that is essentially involved for IgG transport and homeostasis. 
 
MATERIALS AND METHODS 
Cell lines, antibodies and mice 
 
        Human epithelial T84, HT-29, Caco-2, HeLa, and Chinese hamster ovary 
(CHO) cell lines were grown in complete DMEM. Macrophage-like cell line THP-1 
and melanoma FO-1 (β2m-deficient) cell lines were grown in RPMI 1640 
(Invitrogen Life Technologies) complete medium. All complete media were 




nonessential amino acids, and 1% penicillin/streptomycin. Cells were grown in a 
5% CO2 at 37°C. 
Rabbit-anti-FLAG epitope (DYKDDDDK, a single letter for amino acid) or mAb 
LN-2 for human CD74 was purchased from Sigma. HRP-conjugated rabbit anti-
mouse or donkey anti-rabbit antibody was from Pierce (Rockford). The hybridoma 
12CA5, which reacts with the influenza hemagglutinin (HA) epitope, was purchased 
from ATCC. Biotin-labeled mAb for Ii was from Southern Biotechnology. Anti-
lysosome-associated membrane glycoprotein-1 (anti-LAMP-1; mouse IgG1, clone 
H4A3, rat IgG2a, clone 1D4B, developed by Drs. T. August and J. Hildreth) was 
obtained from the Developmental Studies Hybridoma Bank developed under the 
auspices of the National Institute of Child Health and Human Development and 
maintained by the University of Iowa (Iowa City, IA). Mab anti-EEA1, FITC-
conjugated mAb anti-LAMP-1, rat anti-mouse Ii (In-1), and rat anti-mouse 
transferrin receptor were obtained from BD Biosciences. Alexa 488, Alexa 555, and 
Alexa 633 fluor-conjugated secondary antibodies were from Molecular Probes. 
Recombinant human IFN-γ, IL-4 and GM-CSF were from R&D Systems.  
 
Homozygous Balb/c Ii-/- mice (217), originally obtained from Dr. Elizabeth 
Bikoff (University of Oxford, England, UK), were bred in a specific pathogen free 
facility at the National Institutes of Health animal facilities. BALB/c/J mice were 





Production of Affinity-purified FcRn antibodies 
        The human FcRn codons corresponding to the 299-343 or mouse FcRn codons 
427-472 were amplified by PCR and subcloned into the pGEX4T-1 (Amersham 
Pharmacia Biotech) expression vector. Production of affinity-purified glutathione S-
transferase fusion proteins was as previously described (153). For production of 
anti-FcRn peptide antibody, peptide CLEWKEPPSMRLKARP was synthesized by 
Invitrogen.  The immunization of rabbits with purified fusion protein or FcRn 
peptides coupled with keyhole limpet hemocyanin was carried out by Rockland 
Immunochemicals. Anti-FcRn antibodies were affinity-purified from rabbit sera 
with affinity columns, respectively. 
 
Reverse Transriptase (RT)-PCR analysis 
        For total RNA extraction, cells were pelleted and resuspended at a 106 cells/ml 
in Trizol Reagent (Invitrogen Life Technologies). The human Ii gene was amplified 
by primers (5’-TCCCAAGCCTGTGAGCAAGATG-3’, 5’-
CCAGTTCCAGTGACTCTTTCG-3’) with one step RT-PCR kit (Qiagen). The 
mRNA was also amplified by glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH)-specific primers (5’-GAGAAGGCTGGGGCTCAT-3’, 5’-
TGCTGATGATCTTGAGGCTG-3’) as an internal control to monitor the quality of 
the RNA purification and cDNA synthesis. The PCR products were analyzed by 1.5 








Construction of FcRn wild-type, mutant, and invariant chain expression vector 
       The constructions of human β2m and FcRn expression plasmids, pCDNAβ2m 
and pcDNA-FLAGFcRn, have been described previously (153). The pcDNA-
FLAGFcRn construct fused with a preprotrypsin signal sequence, FLAG epitope, 
into the amino terminus of the human FcRn gene (1-342 aa). PCR primer pair 
(5’ATAAGAATGCGGCCGCGGCAGAAAGCCACCT CTCCCT-3’, 5’-
TGCTCTAGATTACCTCATCCTTCTCCACAACA-3’) was used to construct a 
plasmid encoding FLAG-tagged FcRn mutant (1-302 aa) that lacks the cytoplasmic 
tail. The DNA fragment was digested with Not I and Xba I and ligated into the 
plasmid pCDNAFLAG to generate the plasmid pcDNAFLAGFcRn-TD. To 
generate pcDNAFLAGFcRn-LL/AA, FcRn cDNA in a pCDNAFLAG was used as 
the template for site-directed mutagenesis by an in vitro Transformer Site-directed 
Mutagenesis Kit (Clontech). The oligonucleotide (5’-
CACCGGGGTCGCCGCGCC CACCCCA-3’) was used for mutation of leucine 
residues 320-321 to alanine residues (base substitutions are underlined). To 
construct pcDNAFLAGmFcRn, PCR primer pair (5’-
TCACAAGCTTTCAGAGACCCGCCC CCCACTGATGTAT-3’, 5’-
TGATCTAGACTAGGAAGT GGCTGGAAAGGCA) was used. The DNA 
fragment was digested with HIND III and Xba I (underlined in primers) for cloning. 
PCR primer pair (5'-CCGCTCGAGTCAGAGGCTAGCATAA 
TCAGGAACATCATACGGATACATGGGGACT GGGCCCAGA, 5'-
ATAAGAATGCGGCCGCT TCCGAGATGCACAGGAGGAGA-3') was used to 




DMcyt and phFcRn-Iicyt were constructed by two-step PCR reactions cloning PCR 
fragments into pCDNAFLAG. The cytoplasmic tail codons (222-245 aa) of HLA-
DM were amplified by primer pair (5’-
GTAGGAGGAGCTCTGTTGTGGAGAGCTGGCCA CTCTAGTTA-3’, 5’-
TCTCTCTAGACTAG GAAATGTGCCATCCTT-3’). The Ii cytoplasmic tail (1-
46 aa) was synthesized by Integrated DNA Technologies. The amplified HLA-DM 
or synthesized Ii chain cDNA fragments contain an overhanging sequence 
complementary to the FcRn cDNA. In the second step, fragments of Ii or HLA-DM 
were annealed to FcRn plasmid and a fusion product of both cDNA fragments was 
synthesized by PCR primer pairs specific for FcRn and Ii or HLA-DM. In all above 
cloning, the primer introduced a Not I or Xba I site (underlined) to facilitate 
cloning. The plasmid encoding the N-glycosylation mutant (FcRn N/S) of human 
FcRn was generated by replacing the consensus glycosylation sequence, Asn-X-
(Ser/Thr) for change of asparagine 102 to a serine residue (213). All constructs 
were sequenced to verify the fidelity of the amplification and cloning. The human 
Ii.Δ91-99 or Ii.M91A in pCDNA3 vectors was a kind gift from Dr. Norbert Koch 
(218). The plasmid pTFR-GFP was obtained from Dr. Gary Banker (Oregon Health 
& Science University, Portland, Oregon). The plasmid pcEXV3-mIi 31, coding for 
wild-type mouse (m)Ii 31, was a kind gift from Dr. Ronald N. Germain (National 
Institutes of Health, Bethesda, Maryland). 
 




The stable cell lines, HeLaFcRn, FO-1FcRn and FO-1FcRn+β2m, have been 
described previously (153, 213). HeLa or HeLaFcRn cells were transfected with 
pBUDCE4-Ii vector with Effectene transfection reagent (Qiagen). Stable 
transfectants were selected by G418 or G418 plus zeocin for single or double 
transfectants, respectively. Positive clones were tested for protein expression 
through Western blot using anti-FLAG or -HA Ab. Transfectants were maintained 
in medium containing G418 (500 μg/ml) and/or Zeocine (150 μg/ml). For transient 
transfections, cells were transfected with the 2 μg plasmid pBUDCE4-Ii. Protein 
expressions were examined 48 h after transfection. 
 
Western blotting, immunoprecipitation, and gel electrophoresis 
Cell lines and transfectants were lysed in 0.5% CHAPS in PBS with a 
cocktail of protease inhibitor (Roche). Protein concentrations were determined by 
Bradford assay (Bio-Rad Laboratories). The lysates were resolved on a 12% SDS-
PAGE gel under a reducing condition. Proteins were electrotransferred onto a 
nitrocellulose membrane (Schleicher & Schuell). The membranes were blocked 
with 5% non-fat milk, probed separately with anti-FcRn or Ii Ab for 1 h, and 
followed by incubation with HRP-conjugated rabbit anti-mouse or donkey anti-
rabbit Ab. All blocking, incubation, and washing were performed in PBST solution 
(PBS and 0.05% Tween 20). Proteins were visualized by the ECL (Pierce). 
Immunoprecipitation was done as described previously (219). Protein was 
precipitated with anti-FLAG or -HA mAb. The immunoreactive products were 






          Endo-N acetylglucosaminidase H (endo-H) (New England Biolabs) 
digestions were performed as described previously (219). For FcRn digestion in 
immunoprecipitates, proteins were resuspended in 0.5 ml of endo-H digestion 
buffer (100 mM sodium acetate, pH 5, 150 mM NaCl, 1% Triton X-100, 0.2% SDS, 
and 0.5 mM PMSF). Beads containing antibody-antigen complexes were pelleted 
and then eluted with reducing sample buffer. A mock digestion without enzymes 
was performed for each digestion. All digestions were performed for 18 h at 37°C. 
Proteins were analyzed on a 12% SDS-PAGE gel under reducing conditions and 
immunoblotted with anti-FLAG Ab. 
 
IgG binding assay
         IgG binding assay was performed as previously described (2, 6). Cells were 
lysed in PBS (pH 6.0 or 7.5) with 0.5% CHAPS (Sigma) and protease inhibitor 
cocktail on ice for 1 hr. Post-nuclear supernatants containing 0.5–1 mg of soluble 
proteins were incubated with human IgG-Sepharose (Amersham Pharmacia 
Biotech) at 4°C overnight. The unbound proteins were removed with PBS (pH 6.0 
or 7.5) containing 0.1% CHAPS. The adsorbed proteins were boiled with reducing 
electrophoresis sample buffer at 95°C for 5 min. The eluted fractions were subjected 





Isolation of human monocyte-derived dendritic cells (DC), knockdown of 
CD74 in DC by small interfering RNA (siRNA), and generation of bone 
marrow-derived DC (BMDC) from mice. 
         Human immature DCs were obtained by culturing the adherent fraction of 
normal human PBMCs (Institute of Human Virology, Baltimore, MD) in the 
presence of GM-CSF and IL-4 as previously described (6). Briefly, monocytes were 
isolated from PBMCs by adherence to plastic Petri dish for 2 h and then cultured for 
6 days in RPMI 1640 complete medium containing human GM-CSF (50 ng/ml) and 
100 ng/ml IL-4 (R&D). The medium was replaced every 3 days. The 1 X 10  
immature DC cells were transfected with 2.5 ug mission  shRNA plasmid for 
human CD74 (Sigma) in 100 μl nucleofactor solution 
6
TM
using a DC nucleofection kit 
(Amaxa, Cologne, Germany) according to the instructions of the manufacturer. 
Cells were then resuspended with RPMI 1640 medium and cultured on coverslip. 
After 24 h, cells were fixed, permebilized, and stained for confocal microscope 
analysis. 
      
       Bone marrow-derived DCs from wild type BALB/c and Ii-/- mice were 
generated as previously described (220). Immature DCs were purified from 
CD11c+ magnetic microbeads contained columns (MACS, German) and 







         Immunofluorescence was performed based on methods previously described 
(2, 10). Briefly, cells were cultivated on coverslips for 24 h. The cells were rinsed in 
PBS and cold-fixed in 3.7% paraformaldehyde (Sigma) in PBS for 30 min at 4°C 
and quenched with glycine for 10 min. After two washings with PBS, the coverslips 
were permeabilized in solution (PBS containing 0.2% Triton X-100) for 20 min, 
then blocked with blocking buffer containing 3% normal goat serum. Cells were 
incubated with affinity-purified primary antibody in PBST with 3% BSA for 1 h. 
Cells were then incubated with Alexa 555 Fluro-conjagated goat anti-mouse IgG 
and Alexa 488 Fluro-conjugated goat anti-rabbit IgG in blocking buffer. After each 
step, cells were washed at least three times with 0.1% Tween-20 in PBS. Coverslips 
were mounted on slides with ProLongTM antifade kit (Molecular Probes) and 
examined using a Zeiss LSM 510 confocal fluorescence microscopy. The images 
were processed using the LSM Image Examiner software (Zeiss, Germany). 
Quantitative colocalization measurement was performed using the Zeiss LSM 510 
Examiner Software. Pearson’s correlation coefficient was calculated for describing 
the colocalization correlation of the intensity distributions between two channels. In 
each quantitative experiment with transfected HeLa cells, 15 cells in total were 
analyzed. For immature DCs, 10 cells in total were analyzed. P<0.05 was 
considered as significant.  
RESULTS 




         HeLa is an Ii and FcRn double negative cell line. To test whether Ii chain 
interacts with FcRn molecule, HeLaFcRn or HeLamock cells were transfected with 
plasmids encoding HA-tagged Ii cDNA. Cells were lysed with a low-stringency 
CHAPS buffer and subjected to immunoprecipitation with either an anti-FLAG (for 
FcRn) or anti-HA (for Ii chain) Ab. The immunoprecipitate was analyzed by 
blotting with an anti-HA (Fig. 2.1A) or anti-FLAG Ab (Fig. 2.1B). As shown in 
Fig. 2.1, anti-FLAG Ab co-immunoprecipitated Ii (Fig. 2.1A, lane 3). The anti-HA 
mAb co-immunoprecipitated FcRn HC (Fig. 2.1B, lane 1). Interaction between 
FcRn and Ii was further analyzed by confocal microscopy (Fig. 2.1C). As expected, 
both FcRn and Ii appeared as punctuate and vesicular staining. They were 
colocalized with each other (Fig. 2.1C, right panel). In addition, the association of 
FcRn and Ii could be maintained in the presence of other detergents such as 0.5% 
Triton X-100 (Fig. 2.1D, lane 1) and NP-40 (Fig. 2.1D, lane 2); however, the 
association was disrupted by 0.5% SDS (Fig. 2.1E, lane 3). Therefore, these data 
show that Ii specifically associates with FcRn. 
 
Ii chain interacts with both FcRn HC alone and FcRn-β2m complex 
        The functional FcRn molecule consists of an FcRn HC and β2m. We have 
previously expressed FcRn alone, or, with β2m together in FO-1 cells (213). FO-1 is 
a melanoma cell line that lacks β2m expression. To test whether Ii chain interacts 
with FcRn HC alone or in an FcRn-β2m complex, the cell lysates were generated 
from FO-1mock, FO-1FcRn, and FO-1FcRn+β2m cells that were transiently transfected 







FIGURE 2.1. FcRn interacts with the Ii chain. Cell lysates were immunoprecipitated 
(IP) with Abs and the immunoprecipitates were subjected to 12% SDS-PAGE 
electrophoresis under reducing conditions, then transferred to a nitrocellulose membrane 
for Western blotting. Immunoblots (IB) were developed with ECL. Each experiment was 
performed at least twice.  
A+B. The cell lysates from HeLaFcRn (lane 1), HeLaIi (lane 2), and HeLaFcRn+Ii (lane 3) were 
immunoprecipitated by anti-FLAG M2 mAb or anti-HA mAb. The immunoprecipitates 
were subjected to Western blotting with anti-HA or FLAG mAb as indicated.  
C. Colocalization of FcRn and Ιi in HeLaFcRn+Ii. Cells grown on glass coverslips were fixed 
with 3.7% paraformaldehyde and permeabilized in 0.2% Triton X-100. Subsequently, the 
cells were incubated with affinity-purified rabbit anti-FLAG (FcRn, left panel) or anti-ΗΑ 
(Ii, middle panel) specific Ab, followed by Alexa Fluro 488- or 533-conjugated IgG. 
Puncta that appear yellow in the merged images (right panel) indicate colocalization of 
FcRn with the Ii chain. Scale bar represents 5 μm. 
D. HeLaFcRn+Ii cell lysates were generated by 0.5% Triton X-100 (lane 1), NP-40 (lane 2), 
SDS (lane 3), and CHAPS (lane 4) buffers and immunoprecipitated by HA-specific Ab. 
The immunoprecipitates were subjected to Western blot analysis. The location of the FcRn 







FLAG Ab for FcRn or anti-β2m mAb, BBM1. The immunoprecipitates were 
sequentially blotted with anti-HA for Ii chain (Fig.2. 2A, lanes 2 and 3) and FLAG 
Ab for FcRn (Fig. 2.2B, lane 3). The results showed that Ii was detected in either 
FLAG immunoprecipiates from FO-1FcRn or anti-β2m immunoprecipiates from FO-
1FcRn+β2m. We were unable to co-immunoprecipitate the FcRn HC and Ii chain from 
the lysates of untransfected FO-1 cells by anti-β2m Ab, suggesting the specificity. 
Therefore, we conclude that Ii interacts with both FcRn heavy chain alone and 
FcRn-β2m complex. To further confirm the presence of FcRn–Ii complex in the ER 
and Golgi apparatus, HeLaFcRn+Ii cells were lysed in CHAPS buffer; anti-Ii (LN-2) 
immunoprecipitates were subjected to Endo H digestion. Human FcRn possesses 
one N-linked glycosylation site. As shown in Fig. 2C, FcRn HC in an Ii 
immunoprecipitate from HeLaFcRn+Ii cells exhibited a mixture of sensitivities to 
Endo H digestion (Fig. 2.2C, lane 5) as compared to mock digestion (Fig 2.2C, lane 
4). Endo H sensitive FcRn HC had a similar mobility as FcRn N/S (Fig 2.2C, lane 
1), an N-glycan mutant of FcRn (213). These data show that Ii-associated with both 
both endo H-sensitive and -resistant forms of FcRn, corresponding to post-ER 
modification of the glycan structure, and therefore, supporting the initiation of the 
FcRn–Ii interaction in the ER and maintenance during transport through the Golgi 












FIGURE 2.2 Ii chain interacts with both FcRn HC alone and FcRn H-β2m complex. All 
immunoprecipitates were subjected to Western blotting analysis. Blots were developed 
with ECL. Each experiment was performed at least three times. Only the region of interest 
in the gel is shown.  
A+B. The FO-1mock (lane 1), FO-1FcRn (lane 2) and FO-1FcRn+β2m (lane 3) cells were 
transiently transfected with pBUDCE4Ii-HA. After 48 h, cell lysates were 
immunoprecipitated by anti-FLAG M2 mAb (A) or anti-β2m mAb BBM1 (B). The 
immunoprecipitates were blotted with anti-HA (Ii, 1st blot) or rabbit anti-FLAG (FcRn, 2nd 
blot) Ab. The cell lysates from HelaFcRn+Ii were used as a positive control for 
immunoblotting (B, lane 4).  
C. Sensitivity of Ii-associated FcRn HC to Endo H digestion. The lysates (500 μg) from 
HeLaFcRn (lanes 2 and 3), HeLaFcRn+Ii (lanes 4 and 5) and HeLa (lane 6) were 
immunoprecipitated by HA mAb. The immunoprecipitates were digested by mock (lanes 3 
and 4) and Endo H (lanes 2, 5, and 6) for 18 h, respectively. Lane 5 represented a mixture 
of Endo H-sensitive (HS) and -resistant (HR) FcRn proteins. The cell lysates from glycan 







FcRn associating with Ii chain can bind to IgG in acidic pH 
 FcRn binds IgG at acidic pH 6.0 and releases IgG at neutral pH. We tested whether 
the the association of FcRn with Ii affects its ability to bind to its natural ligand 
IgG. We incubated cell lysates from HeLa cells expressing FcRn and/or Ii with 
human IgG-Sepharose at either pH 6.0 or pH 7.5. Cell lysates from HeLaFcRn cells 
were used as positive control. The binding elutes and cell lysates were subjected to 
the Western blot analysis. As expected, FcRn from HeLaFcRn cells bound to IgG at 
pH 6.0 (Fig. 2.3, lane 2), but not at pH 7.5 (Fig.2.3, lane 1). Similarly, FcRn from 
HeLaFcRn+Ii cells bound to IgG at pH 6.0 (Fig. 2.3, lane 4), but not at pH 7.5 (lane 
3). Both Ii and FcRn were detected in the binding elutes of human IgG beads, 
suggesting the presence of Ii in FcRn-IgG complexes. Hence, it is very likely that 
Ii-association does not interfere with FcRn function in the IgG binding assay. 
 
CLIP is not required for the interaction of Ii with FcRn 
        Human Ii has a short, 30 amino acids (aa), N-terminal cytoplasmic tail, 
followed by a single 24 aa transmembrane region and an ~150 aa long lumenal 
domain (Fig. 2.4A). A segment of residues 81-104 is called class II associated 
invariant chain peptide (CLIP). The CLIP region contains a central 9 amino acid 
sequence, MRMATPLLM (91-99 aa), which is conserved among human, mouse 
and rat (Fig. 2.4A). Analysis of MHC class II supermotifs (221) and the crystal 
structures of CLIP complexed with MHC class II molecules (222) indicate the 














FIGURE 3.3. FcRn/li chain complex in IgG binding. HeLa transfectants as indicated were 
lysed in sodium phosphate buffer (pH 6.0 or 7.5) with 0.5% CHAPS and proteinase 
inhibitors. Approximately 0.5 mg of the soluble proteins was incubated with human IgG-
Sepharose at 4°C. The eluted proteins or cell lysates were subjected to Western blotting 
analysis. Proteins were probed with rabbit anti-FLAG Ab or anti-ΗΑ mAb and developed 
with HRP-conjugated Abs and ECL. The locations of the human FcRn HC and Ιi chain are 




class II. In addition, different MHC class I alleles display different dependencies 
upon the sequence of CLIP (223). Therefore, it is pertinent to assess whether the 
CLIP or its methionine 91 is important for the interactions of Ii with FcRn. To do 
so, the CLIP region of Ii chain was deleted, or methionine 91 was replaced with 
alanine (construct Ii.M91A). The ability of these Ii mutants to associate with FcRn 
molecule is tested using HeLaFcRn cells transiently transfected with these Ii 
constructs. Deletion of CLIP (Fig. 2.4B, lane 3) or substitution of methionine at 
position 91 (Fig. 2.4B, lane 2) did not appreciably alter the ability of Ii association 
with FcRn, as shown by the immunoprecipitation-Western-blot analysis. HelaFcRn 
(Fig. 2.4B, lane 1) or isotype-matched IgG (lane 5) was used as a positive or 
negative control in this assay. Taken together, these data suggest that the CLIP (91–
99) is not required for binding to the FcRn. 
 
Both Ii and the cytoplasmic tail of FcRn targets FcRn into the early endosomes 
        Immunofluorescence microscopy studies showed that in HeLaFcRn transfectant, 
a high proportion of the FcRn colocalized with the early endosomal marker, EEA1 
(Fig. 2.5A, upper panel), indicating a preferential distribution of FcRn to the early 
endosomes. The expression of Ii in HeLaFcRn cells did not significantly change the 
steady-state distribution of FcRn and EEA1 (Fig.2.5A, bottom panel). An FcRn 
mutant that lacks its cytoplasmic tail (FcRn-TD) was immunoprecipitated with Ii 
(Fig. 2.5B, lane 2), indicating that the cytoplasmic tail of FcRn is not necessary for 








FIGURE 2.4. Function of CLIP in the Ii association with FcRn. 
A. Schematic representation of the full-length li chains. TMD: the transmembrane domain, 
CLIP: the class II-associated Ii chain peptide. Ii chain sequence alignment of human 
(Accession No. 10835070), mouse (13097485) and rat (37589621) indicates conservation 
of the CLIP (91–99) regions.  
B. CLIP (91–99) is not important for interaction with FcRn.  HeLaFcRn cells were 
transiently transfected by plasmid pCDNA3 encoding the full-length Ii chain (Ii), Ii.Δ91-
99, and Ii.M91A, respectively. After 48 hr, the cell lysates were immunoprecipitated by 
anti-Ii mAb (lanes 1-3) and an isotype-matched IgG control (lane 5). The cell lysates from 
HeLa (lane 4) or HeLaFcRn+Ii (lane 6) were used as a negative or positive control. The 
immunoprecipitates were subjected to Western blotting with FLAG-specific Ab and HRP-
conjugated goat anti-rabbit Ab, and finally visualized with ECL.  




altered the cellular distribution pattern of FcRn appearing as honeycomb with rare 
colocalization with EEA1 (Fig. 2.5C, upper panel). However, HeLaFcRn-TD cells 
transfected with Ii chain resulted in a significant redistribution of FcRn-TD into an 
EEA1 positive intracellular compartment (Fig. 2.5C, lower panel; Fig. 2.5D). This 
result suggests that the association of Ii and FcRn is functional and has the ability to 
drive associated FcRn into the early endsomes independently of the FcRn 
cytoplasmic tail. 
 
Ii directs FcRn to the late endosomes/lysosomes 
        In HeLaFcRn cells, the majority of FcRn appeared in the early endosomal 
compartment (Fig. 2.5A, upper panel) and did not colocalize well with LAMP-1 
marker (Fig. 2.6A, upper panel), a marker for late endosomal/lysosomal 
compartments. To determine the effect of Ii expression on the cellular distribution 
of FcRn, we examined the intracellular FcRn distribution by immunofluorescence 
staining in HeLaFcRn+Ii cells. In comparison with HeLaFcRn, co-expression of Ii 
greatly increased the colocalization of FcRn with LAMP-1 (Fig. 2.6A, lower panel; 
Fig. 2.6E). As expected, FcRn-TD, when expressed alone, exhibited a honeycomb 
appearance and had limited colocalization with LAMP-1 (Fig. 2.6B, upper panel).  
Co-transfection of HeLa cells with both FcRn and Ii chain resulted in a 
redistribution of FcRn-TD into an intracellular compartment that largely overlapped 
with the LAMP-1 (Fig.2.6B, lower panel; Fig. 2.6E). 






FIGURE 2.5. Ii chain redirects tailless FcRn-TD to the early endosome. Scale bars 
represent 5 μm. 
A. The endocytic trafficking of FcRn in HeLaFcRn and HeLaFcRn+Ii transfectants. 
HeLaFcRn cells were transiently transfected with pBUDCE4 or pBUDCE4-Ii vector. 
Cells were fixed, permeabilized and co-stained for FcRn (in green) or early 
endosomal marker EEA1 (in red). Puncta that appear yellow in the merged images 
(right panel) indicate colocalization of FcRn with the EEA1.  
B. The association of tailless FcRnTD with the Ii chain. The cell lysates from 
HeLaFcRnTD (lane 1), HeLaFcRnTD/Ii (lane 2), and HeLaFcRn/Ii (lane 3) were 
immunoprecipitated by anti-HA mAb. The immunoprecipitates were subjected to 
Western blot. Immunoblots (IB) were blotted with rabbit anti-FLAG Ab and HRP-
conjugated goat anti-rabbit Ab. The blot was developed with ECL.  
C. Immunofluorescence analyses of HeLa cells expressing either tailless FcRn-TD 
alone (upper panel) or FcRn-TD and Ii (lower panel). Transfected cells were fixed, 
permeabilized, and stained with an Ab to FLAG (in green) or EEA1 (in red). The 
arrows indicate the colocalization (in yellow) of the proteins.  
D. Averages of the colocalization coefficients in panel A and C. Pearson’s 
correlation coefficient were calculated. For each experiment, fifteen cells were 






         It is possible that over-expression of Ii non-specifically alters the endocytic 
system (224), consequently resulting in a redistribution of tailless or full-length 
FcRn into the LAMP-1+ compartment. Hence, we followed the effect of over-
expression of Ii on the cellular distribution of GFP-fusion of transferrin receptor 
(TfR-GFP), an endosome marker. TfR-GFP was found to be predominantly 
accumulated in early endosomes in either the presence (Fig. 2.6C, upper panel) or 
absence (Fig. 2.6C, lower panel) of Ii expression, and did not significantly route to 
the LAMP-1+ compartment in HeLaFcRn (Fig. 2.6D, upper panel) or HeLaFcRn+Ii 
cells (Fig. 2.6D, lower panel; Fig. 2.6E). This suggests that Ii over-expression did 
not result in the redistribution of TfR from early endosome to the LAMP-1+ 
compartment. These results indicate that the Ii specifically targets FcRn from the 
early endosome to the late endosomes/lysosomes without significantly modifying 
the endocytic pathway.    
           To further study the effect of Ii on FcRn trafficking in cells naturally 
expressing both FcRn and Ii molecules, we examined the intracellular distribution 
of FcRn in PBMC-derived DCs using immunofluorescence with affinity-purified 
FcRn-specific Ab. In immature DCs, FcRn colocalized with both EEA1 (Fig. 2.7A, 
upper panel) and LAMP-1 markers (Fig. 2.7A, lower panel), verifying the cellular 
location of FcRn in both early and late endosomes/lysosomes. The colocalization of 
FcRn (green) and Ii (blue) with LAMP-1 (red) was observed in immature DCs, 
which appeared as white (Fig. 2.7B, lower panel). To test the role of Ii in targeting 
of FcRn to the late endosomal/lysosomal compartment in human immature DCs, we 





FIGURE 2.6. Ii chain directs FcRn to the late endosome/lysosome compartment. Merged 
images are shown in the right panels. The yellow in the merged images indicate 
colocalization of FcRn with EEA1 or LAMP-1 marker. Similar experiments were observed 
from three independent experiments. The arrows indicate the colocalization of the proteins. 
Scale bars represent 5 μm. 
A+B. Lysosomal sorting of full-length FcRn (A) or tailless FcRn-TD (B) in the presence of 
Ii chain expression. HeLaFcRn or HeLaFcRn+Ii cells were fixed, permeabilized, and 
immunostained for LAMP-1 (in red) or FcRn (in green), followed by Alexa 555 or 488 
Fluro-conjagated IgG. 
C+D. Localization of transferrin receptor (TfR) in HeLaFcRn or HeLaFcRn+Ii cells. HeLaFcRn 
or HeLaFcRn+Ii cells were transiently transfected with pcDNA-TfR-GFP, fixed, 
permeabilized, and immunostained for EEA1 (C) or LAMP-1 (D) marker. Transferrin 
(TfR) was directly visualized by GFP fluorescence (in green), EEA1 or LAMP-1 is shown 
in red. Merged images are represented in the third panel of each row.  
E. Averages of the LAMP-1 colocalization coefficients in panel A, B, and D. Pearson’s 





colocalization of FcRn with LAMP-1 staining was significantly decreased (Fig. 
2.7B, upper panel; Fig. 2.7C), suggesting FcRn failing to colocalize with LAMP-1 
marker when Ii was knocked down.  
       
         To examine the role of mouse Ii chain in mouse FcRn (mFcRn) trafficking. 
We first determined the interaction of mFcRn and ii using co-immunoprecipitation. 
The anti-FLAG Ab for mFcRn immunoprecipitate was analyzed by immunoblotting 
for Ii chain (Fig.2.8A). Anti-FLAG Ab co-immunoprecipitated mouse Ii chain (Fig. 
2.8A, lane 1) in CHO cells expressing both mFcRn and murine Ii chain, but not in 
CHO cells expressing Ii (lane 2) or mFcRn (lane 3) alone, further confirming the 
association of mFcRn with Ii. To test the IgG-binding ability of mouse FcRn-ii 
complexes, we incubated cell lysates from mouse bone marrow-derived DC 
(BMDC) at either pH 6.0 or pH 7.4 with IgG-Sepharose. Cell lysates from 
CHOmFcRn cells were used as a positive control. The binding elutes or cell lysates 
were analyzed using Western blot for either Ii or mFcRn. Both Ii and mFcRn were 
detected in the elute from IgG beads (Fig.2. 8, lane 1). As expected, mFcRn-Ii from 
BMDC cells bound to IgG at pH 6.0 (Fig. 2.8, lane 1), but not at pH 7.4 (Fig. 2.8, 
lane 2). These data confirm that like human Ii chain, the murine Ii chain also 
interacts with the mFcRn-IgG complexes. To examine the role of mouse Ii in the 
routing of mFcRn to the late endosomes/lysosomes, we compared the cellular 
distribution of mFcRn in BMDCs from wild type and Ii-/- mice. In immature BMDC 
from Ii-/- mice, the colocalization between mFcRn and LAMP-1 staining was 




FIGURE 2.7. FcRn appearance in the late endosome/lysosome of human immature 
dendritic cells (IDCs) is dependent on the Ii chain expression. Human IDCs were obtained 
by culturing human PBMCs in the presence of GM-CSF and IL-4 for 6 days. Cells grown 
on glass coverslips were fixed and permeabilized before staining. The bars represent 5 μm. 
A. Colocalization of FcRn (in green) and EEA1 or LAMP-1 (in red) in DC cells. The IDCs 
were incubated with affinity-purified rabbit anti-FcRn, mAb anti-EEA1 or LAMP1 
antibody, followed by Alexa 555 or 488 Fluro-conjagated IgG of the corresponding 
species. Punctuate staining that appears in yellow in the merged images indicates (right 
panels) the colocalization of FcRn with the endosomal or lysosomal marker. The arrows 
indicate the colocalization of the proteins.B. FcRn trafficking to the late 
endosome/lysosome becomes less in Ii-depleted IDC. Human IDCs were transfected with Ii 
siRNA plasmid (top pane) or vehicle (bottom panel). Cells were immunostained for FcRn 
(in green), LAMP-1 (in red), and Ii (in blue). Colocalization of all three molecules appears 
in white (lower panel, inset). Similar results were observed from at least three independent 
experiments.  
C. Averages of the LAMP-1 and FcRn colocalization coefficients in IDC transfected with 
vehicle (mock) or Ii siRNA plasmid in panel B. Pearson’s correlation coefficient was 





with the colocalization level in BMDC from wild-type mice (Fig. 2.8C, lower panel 
and Fig.2. 8D), suggesting the majority of mFcRn fails to colocalize with LAMP-1 
marker when Ii is knocked out. These data confirm that the targeting of endogenous 
FcRn in human immature DCs (Fig. 2.7C) or mouse BMDC (Fig. 2.8D) to the late 
endosomes lysosomes is significantly dependent on Ii.   
  
Ii chain interacts with FcRn and directs FcRn into the late 
endosomes/lysosomes under inflammatory conditions 
        In addition to the expression in macrophages and DCs, FcRn is also expressed 
in epithelial and endothelial cells. Under physiological conditions, most epithelial 
and endothelial cells are Ii-negative. However, the Ii chain can be induced for 
expression in these types of cells by proinflammatory cytokines, such as IFN-γ or 
bacterial infections (225). Hence, we verified the induction of Ii in the intestinal 
epithelial HT-29 and T84 (Fig. 2.9A), primary endothelial (Fig. 2.9B), and HeLa 
cells upon exposure to IFN-γ. Caco-2 cells showed Ii chain expression by PCR even 
in absence of induction by gamma-IFN (Fig. 2.9B). Co-immunoprecipitation of 
FcRn with anti-Ii Ab from the lysates of HeLaFcRn or THP-1 cells treated with IFN-γ 
showed the Ii–FcRn association in IFN-γ-stimulated HelaFcRn  (Fig. 2.9C) or THP-1 
cells (Fig. 2.9D). However, we were unable to co-immunoprecipitate the FcRn HC 
from the lysates of HeLaFcRn cells that were not treated with IFN-γ by anti-Ii mAb, 








FIGURE 2. 8. Mouse FcRn appearance in the late endosome/lysosome of bone marrow-
derived dendritic cells (BMDC) is significantly dependent on the Ii expression.  
A. Mouse FcRn associates with mouse Ii chain. The cell lysates from CHO cells transiently 
with plasmids encoding murine Ii and mFcRn (lane 1), Ii (lane 2), and mFcRn cDNA (lane 
3) were immunoprecipitated by anti-FLAG M2 mAb. The immunoprecipitates were 
subjected to Western blotting with anti-Ii (In-1) or FLAG mAb as indicated. Immunoblots 
were developed with ECL. 
B. The mFcRn/li complex in IgG binding. BMDCs were lysed in PBS (pH 6.0 or 7.5) with 
0.5% CHAPS and proteinase inhibitors. Approximately 0.5 mg of the soluble proteins was 
incubated with IgG-Sepharose at 4°C. The eluted proteins (Lanes 1 and 2) or cell lysates 
(lane 3) were subjected to Western blotting. Proteins were probed with anti-Ιi (In-1) or 
rabbit anti-FLAG Ab and developed with HRP-conjugated secondary Abs and ECL. The 
locations of mFcRn HC and Ιi (p31 and p41) are indicated by arrows.  
C. Colocalization of FcRn (in green) and LAMP-1 (in red) in BMDC cells. The BMDC 
from Ii -/- (top panel) or wild type (bottom panel) mice was incubated with affinity-purified 
rabbit anti-FcRn or mAb anti-LAMP-1 Ab, followed by Alexa 555 or 488 Fluro-conjagated 
IgG of the corresponding species. The yellow and arrows indicate the colocalization of 
FcRn with LAMP-1. Scale bars represent 5 μm. 
D. Averages of the LAMP-1 and FcRn colocalization coefficients in BMDC. Pearson’s 
correlation coefficient was measured for the colocalization correlation of the intensity 
distributions between two channels. The ten cells were analyzed in three different optical 





Furthermore, immunofluorescence staining showed that the colocalization of FcRn 
with Ii and LAMP-1were observed in HelaFcRn cells upon exposure to IFN-γ 
stimulation (Fig.2. 9E and 2.9F, lower panels), but not in mock-stimulated cells 
(Fig. 2.9E and 2.9F, upper panels). This was further confirmed by Pearson’s 
colocalization coefficients of FcRn, Ii, and LAMP-1 staining (Fig.2.9G). Statistical 
data showed the significance of FcRn and LAMP-1 colocalization (Fig.2. 9G).  
Therefore, we conclude that the intracellular trafficking of FcRn can be regulated 
by inflammatory cytokine through induction of Ii expression.  
 
The cytoplasmic tail of Ii is responsible for regulating FcRn trafficking to the 
endosomal and lysosomal compartments  
     We further examined how Ii chain regulates FcRn trafficking inside cells. The 
key signals determining the subcellular location of most membrane proteins are in 
the cytoplasmic tail. The cytoplasmic tail of both human and murine FcRn contains 
a dileucine-based motif (Fig. 2.10A), which is existed in a number of 
endosomal/lysosomal resident proteins (Fig. 2.10A). To examine whether the 
dileucine-based motif of human FcRn is the early endosome targeting signal of 
FcRn, the two leucine residues were mutated into alanine (Fig. 2.10B). The FcRn-
LL/AA mutant showed a honeycomb distribution with little colocalization of the 
EEA1 (Fig. 2.10B, upper panel) or LAMP-1 (Fig. 2.10B, lower panel) marker in 
HeLaFcRnLL/AA cells. This distribution pattern was similar to that of tailless FcRn 
(Fig. 2.10B, upper panel). Therefore, the dileucine motif in the FcRn is 




   
FIGURE 2.9. Ii chain can interact with FcRn under IFN-γ stimulation. A+B. Ii chain was 
expressed in IFN-γ stimulated epithelial and endothelial cells. Intestinal epithelial (A) and 
endothelial (B) cells were incubated with IFN-γ (50 ng/ml) for 48 hr. THP-1 cells were 
used as a positive control for the expression of Ii. Total RNA was extracted. RT-PCR was 
performed for amplification of FcRn. C+D. Association of Ii chain and FcRn in IFN-γ-
treated HeLaFcRn and THP-1 cells. HeLa, HeLaFcRn (C) and THP-1 (D) cells were stimulated 
with or without IFN-γ for 24 h. The cell lysates were immunoprecipitated by anti-Ii mAb. 
Immunoprecipitates were subjected to Western blotting with affinity-purified rabbit anti-
FcRn Ab. Immunoblots (IB) were developed with ECL. E+F. Colocalization of FcRn and 
Ii (E) or LAMP-1 (F) in HeLaFcRn cells without (upper panel) or with (lower panel) IFN-γ 
treatments. Cells were stimulated with or without IFN-γ for 24 h.  HeLaFcRn cells were 
incubated with anti-FLAG (in green), mAb anti-Ii or LAMP-1 (in red) antibody, The 
yellow and arrows (right panels) indicates the colocalization of FcRn with the Ii or LAMP-
1 marker. Scale bar represents 5 μm. 
G. Averages of FcRn and LAMP-1 colocalization coefficients in panel F. Pearson’s 
correlation coefficient were calculated. For each experiment, fifteen cells were analyzed. 




        The two dileucine motifs in the cytoplasmic tail of the Ii molecule are required 
for targeting MHC class II molecules to the endocytic pathway directly from the 
TGN. This suggests the possibility that the cytoplasmic tail of the Ii molecule is 
also responsible for targeting FcRn to the endocytic pathway. To test this 
hypothesis, we expressed a chimeric protein fusing the cytoplasmic tail of Ii to the 
extracellular domain of FcRn (FcRn-Iicyt) (Fig. 2.10C). Since the Ii chain is a type 
II glycoprotein, we also generated a similar chimeric protein to replace the 
cytoplasmic tail of FcRn with that of HLA-DM as a control (Fig. 2.10C). A 
tyrosine-based motif in the cytoplasmic tail of HLA-DM chain has been shown to 
target HLA-DM to the endocytic compartments (226). Similar to full-length FcRn 
in HeLaFcRn cells, the chimeric protein FcRn-Iicyt bound IgG at pH 6.0 (Fig. 2.10C, 
lane 2) but not at pH 7.4 (lane 1) in an IgG binding assay, suggesting that the fusion 
of the Ii cytoplasmic tail did not affect the integrity of FcRn structure. As shown in 
Fig. 2.10D, the cytoplasmic tail of Ii chain targeted FcRn into an intracellular 
compartment that largely overlapped with either EEA1+ (left panel) or the LAMP-
1+ (right panel) marker. As a control, the cytoplasmic tail of HLA-DM chain 
directed FcRn into the LAMP-1+ late endosomal/lysosomal compartment (Fig. 
2.10D), although a relatively small portion of FcRn appeared in the EEA1+ 
compartment in HeLa cells transfected with FcRn-DMcyt. Person’s correlation 
coefficient analysis shows the significance of colocalization of hybrid FcRn-Iicyt 
molecule with endosomal or lysosomal marker (Fig. 2.10E). Taken together, these 
data suggest that cytoplasmic tail of Ii chain, likely two dileucine-based motifs, is 

















FIGURE 2.10. The cytoplasmic tail of Ii chain can direct FcRn trafficking to both the early 
endosomal and late endosomal/lysosomal compartments. The arrows indicate the 
colocalization of the proteins. Scale bars represent 5 μm.  
A. Dileucine-based motifs involved in intracellular sorting and/or cell-surface endocytosis 
that present upstream acidic residues are shown. The critical Lulea (lie, Met, Val) pairs are 
shown in red face and acidic residues at positions upstream of the dileucine are in green 
face. Sequences were taken from the indicated proteins: human, mouse, rat, bovine, and 
swine FcRn, Ii chain, LIMPII (lysosomal integral membrane protein II), tyrosines, sportily 
VMAT2 (vesicular monoamine transporter 2), CI-M6PR (action independent mannose 6-P 
receptor), and CD-M6PR (action dependent mannose 6-P receptor). 
B. Immunofluorescence analyses of HeLa cells expressing FcRn-LL/AA. The dileucine 
motif was replaced by alanine residues (*) in FcRn cytoplasmic tail (top panel). 
Transfected cells were immunostained with a mAb to FLAG, EEA1 or LAMP-1, followed 
by Alexa 555 or 488 Fluro-conjagated IgG.  
C. Schematic representation of the chemeric FcRn-Iicyt or FcRn-HLA-DMcyt. Left panel: 
the extracellular domain of FcRn (21-302 aa) was in frame fused to the cytoplasmic tail of 
Ii (0-31 aa) or HLA-DMβ (222-245 aa) in pCDNAFLAG. Right panel: The chmeric FcRn-
Iicyt bound IgG. HeLa cells expressing FLAG-tagged FcRn-Iicyt (lanes 1 and 2) or 
HeLaFcRn cells (lanes 3 and 4) were lysed at both pH 6.0 and pH 7.4. The IgG binding assay 
was performed. The eluted proteins were subjected to Western blotting with anti-FLAG 
Ab. The blot was visualized by ECL method. 
D. Immunofluorescence analyses of HeLa cells expressing FcRn-Iicyt and HLA-DMcyt. 
Transfected cells were fixed, permeabilized and immunostained with a mAb to FLAG, 
EEA1 or LAMP-1, followed by Alexa 555 or 488 Fluro-conjugated IgG.  
E. Averages of endosomal or lysosomal colocalization coefficients between FcRn LL/AA 
and FcRn FcRn-Iicyt in panels B and D. Pearson’s correlation coefficient were calculated. 
















        The Ii chain was thought to mainly function as an MHC class II chaperone, 
which prevents the binding of endogenous peptides to MHC class II in the ER and 
directs MHC class II to endocytic compartments, where they are loaded with 
antigenic peptides generated from endocytosed proteins (227, 228). However, Ii has 
recently been shown to have additional functions by interacting with other 
molecules, such as with CD44 (229), MHC class I (230), and CD1d molecules 
(231) during T or NKT cell-mediated responses, the macrophage migration-
inhibitory factor to induce the phosphorylation of the extracellular signal-regulated 
kinase-1/2 (232), Helicobacter pylori urease B subunit to stimulate IL-8 production 
(225), and HIV-2 Vpx (233). In this study, we showed a novel role of Ii chain in 
FcRn-mediated IgG transport and catabolism by regulating intracellular trafficking 
of FcRn. 
 
This study provides several lines of evidence to demonstrate the interaction 
of Ii chain with FcRn. First, Ii was co-immunoprecipitated with FcRn in HeLa 
transfectant (Fig.2.1). Furthermore, FcRn colocalization with Ii in HeLa transfectant 
suggests their association in vivo. Second, although the Ii is not constitutively 
expressed in certain types of epithelial and endothelial cells, FcRn/Ii complexes 
were coimmunoprecipitated from these cells when Ii chain expression was induced 
by IFN-γ Fig. 9 , suggesting the interaction of FcRn and Ii in epithelial or 
endothelial cells can be caused under inflammatory conditions. Third, the FcRn/Ii 




biochemical evidence suggests that the FcRn/Ii complexes were formed as early as 
in the ER and remained as a complex when passing through the Golgi stack. Fourth, 
Ii chain interacted with the nascent FcRn HC alone or with FcRn-β2m complex 
(Fig. 2.2), suggesting that the Ii chain may play a role in retaining FcRn HC in the 
ER until assembly of the complex of HC with β2m. This is in agreement with the 
studies showing that Ii chain retains incompletely-folded CD1d HC in the ER (231), 
but in disagreement with studies showing that the Ii–MHC class I association in the 
ER appears to require essentially fully-folded MHC class I because free HC does 
not associate efficiently with Ii chain (223, 234).  
 
  The CLIP fragement of Ii bind to the antigen binding groove of MHC class 
II or I (223). In contrast to the interaction of Ii with MHC class II, the CLIP of Ii is 
not required for interaction of Ii with FcRn due to a narrowed antigen binding 
groove of FcRn.  This raises an interesting question whether CLIP is important for 
the association of Ii with FcRn. Our finding that mutation or deletion of the CLIP 
did not disrupt FcRn-Ii interaction suggests that the CLIP fragment is not directly 
involved in the FcRn-Ii association (Fig. 2.4). It is still possible that the CLIP 
positions itself above the binding groove of FcRn by the flanking sequences. This 
would result in the engagement of Ii to FcRn at multiple sites other than the peptide 
binding groove. The multiple binding sites between Ii and FcRn may enhance the 
interaction. Indeed, the FcRn-Ii complex resisted multiple detergents (Fig. 2.1E). 
Further study is required for mapping FcRn-Ii interaction as described for MHC 















FIGURE 2.11. Two pathways for intracellular trafficking of FcRn. In cells without Ii 
expression, FcRn may reach the cell surface through the secretory pathway and recycle 
between the plasma membrane and endosomes via endocytosis. In the presence of Ii 
expression, a portion of FcRn molecules is associated with the Ii in the ER and is 
targeted to the endosomes and lysosomes via Golgi stack. In the endosome/lysosome, Ii 
was released from FcRn, presumably, by proteolytic cleavage. Ii represents in green, 
FcRn heavy chain in black, and β2m in red. ER, endoplasmic reticulum; EE, early 




        The association of Ii chain with FcRn clearly expands the distribution of FcRn 
within the endocytic pathway. FcRn has been predominantly detected in the early 
endosomes.  The deletion of FcRn cytoplasmic tail alters the distribution of FcRn to 
the cell surface and cytomplasm. The cellular location of tailless FcRn was partially 
restored by the expression of Ii chain (Fig. 2.5).  Furthermore, Ii directs both tailless 
and intact FcRn to LAMP-1+ late endosomes/lysosomes (Fig. 2.5). This observation 
was further verified by the fact that FcRn appeared in the late endosomes/lysosomes 
in wild-type immature DCs (Fig. 2.7 and 2.8) or IFN-γ-treated HeLaFcRn cells 
(Fig.2.9F), but not in Ii-deficient DC (Figs. 2.7 and 2.8). In this aspect, the role of Ii 
in FcRn intracellular trafficking mirrors its role in directing the MHC class II 
intracellular trafficking. Furthermore, our data showed the transplantation of Ii 
cytoplasmic tail conferred tailless FcRn to appear in both early endosome and late 
endosome/lysosome (Fig.2.10D), suggesting the dileucine-based motif in the Ii 
molecule would compensate for the sorting function absent in the tailless FcRn. 
Mutations of the dileucine-based motif in the cytoplasmic tail of FcRn associated 
with a profound loss of its early endosomal location (Fig. 2.10B), suggesting this 
motif is sufficient to direct FcRn to the endosomes at the steady state. Dileucine 
signals have been reported to bind adaptor protein (AP) complexes that are essential 
for intracellular protein sorting (171). The additional two dileucine-based motifs in 
Ii would further enhance the interaction of FcRn-Ii complex with AP complexes, 
leading FcRn trafficking from the early endosome to the late endosome/lysosome. 
We propose that the intracellular locations of FcRn may be controlled by two 




endosomal/lysosomal targeting of FcRn.  This provides flexibility for FcRn traffic 
in Ii-positive or negative cell types.  In Ii negative cell types, FcRn probably traffics 
directly to the cell surface from the TGN and is subsequently internalized into the 
early endosomes. In Ii expressing cell types, Ii-associated FcRn is likely to be 
segregated from the secretory pathway at the TGN and directly targeted to the 
endocytic pathway without access to the plasma membrane (Fig. 2.11), although 
further studies are needed to test this hypothesis.  
 
        What would be the biological consequences of Ii-FcRn association and the 
expanded intracellular trafficking of FcRn as conferred by Ii chain particlularly in 
heightened inflammatory circumstances?  Several speculations can be made. FcRn 
has two known biological functions: transcytosis of IgG across the polarized 
epithelial cells and maintainence of IgG or albumin homeostasis. Under 
physiological conditions, the cytoplasmic tail of FcRn clearly predominates its 
trafficking in the majority of Ii-negative epithelial or endothelial cells to early 
endosomes. However, this pattern of trafficking may be significantly altered in 
inflammatory conditions since Ii expression is induced in epithelial and endothelial 
cells by inflammatory cytokines or during bacterial and viral infections (225). FcRn 
transports normal or pathogen-specific neutralizing IgG across polarized epithelial 
cells, potentially ‘seeding’ mucosal immunity. It remains to be deteremined 
precisely how the altered trafficking to late endosomal/lysosomal compartments in 
Ii expressing epitheleial and endothelial cells would influence the IgG transport and 




protection, one can envision that due to the association of FcRn with Ii, FcRn might 
bind IgG not only in the early endosome, but also in the late endosomal/lysosomal 
compartment, thus extending its boundary for sampling IgG. The evidence that 
FcRn was capable of binding IgG under lysosomal conditions (pH 5.0) (Zhu et al., 
unpublished) makes this event highly likely. Hence, the appearance of FcRn in the 
late endosome/lysosome may function as a second line that salvages the IgG from 
degradation. Second, since MHC class II are most efficiently targeted into 
proximity with antigenic peptides by Ii chain in antigen presenting cells (APCs); it 
is interesting to bring into perspective the known functions of Ii in conventional 
APCs in order to understand the role of FcRn/Ii association in influencing antigen 
presentation. Our previous findings show that the FcRn is expressed in Mφ and DCs 
(153). Since FcRn appears to associate with Ii chain, FcRn and MHC class II might 
occupy the same acidic compartments. In Mφ and DCs, FcγRs can promote the 
internalization of immune complexes into the endosomes and lysosomes to increase 
the efficiency of MHC class II presentation to CD4+ T cells (236). FcRn, on the 
other hand, may mediate the antigen presentation by binding the immune 
complexes in these antigen processing compartments. The evidence that FcRn is 
able to bind immune complexes and IgG in the pH range of endosomes and 
lysosomes (Zhu et al., unpublished data) supports this probability. Therefore, the 
association of Ii chain and FcRn could further influence the antigen presentations. 
Third, FcRn was involved in IgG-mediated phagocytosis with its expression in the 
phagolysosomes in human neutrophils (237). It would be interesting to know 




into the phagolysosomes. Fourth, an N-terminal product, liberated from Ii chain via 
regulated intramembrane proteolysis, has been recently shown to function as a 
transcription factor in activating the NF-κB-dependent transcription program, at 
least in B lymphocytes (238, 239). Our recent finding revealed that the activation of 
NF-B signaling upregulates the level of FcRn expression (240). As a result, co-
expression of Ii chain and FcRn might regulate the FcRn expression.  
 
         In conclusion, this study delineated a novel intracellular destination for FcRn 
trafficking and demonstrated a novel, unexpected function of Ii chain. Our study 
suggests that the intracellular trafficking pathway and functions of FcRn may be 
altered by the association of Ii chain during physiological and inflammatory 
conditions, and points to a potential effect of Ii in modifying IgG functions of FcRn. 
Thus, the association of FcRn with Ii chain is physiologically relevant, and 
appreciation of this process is important to understanding how IgG is transported and 
how IgG levels are maintained throughout the body. Given that Ii chain may function 
at different conditions, it is of interest to examine how these various effects will 













        Vaccine strategies to prevent invasive mucosal pathogens are being sought due to 
the fact that 80-90% of infectious diseases are initiated at mucosal surfaces. However, 
our ability to deliver an intact vaccine antigen across the mucosal barrier for 
induction of the effective immunity is limited. The neonatal Fc receptor (FcRn) 
mediates the transport of IgG across polarized epithelial cells lining mucosal surfaces. 
By mimicking IgG transfer at mucosal surfaces, intranasal immunization with a 
model antigen herpes simplex virus type-2 (HSV-2) glycoprotein gD fused with an 
IgG Fc fragment in the combination of adjuvant CpG resulted in a complete 
protection of wild type, but not FcRn knockout mice that were intravaginally 
challenged with virulent HSV-2 186. The immunization induced efficient mucosal 
and systemic antibody, B and T cell immune responses, including memory immune 
responses which remained stable at least 6 months post-vaccination. These results at 
first demonstrate that the FcRn-IgG transcellular pathway may represent a novel 




Most infectious pathogens initiate their infections through mucosal surfaces of 




elicit systemic humoral and cellular immunity, but also engender mucosal immune 
responses. However, most current vaccines are administered through intramuscular or 
subcutaneous route (209). While these parental immunizations are efficient at 
inducing strong systemic IgG responses, they usually engender low mucosal 
immunity. The continued emergence of clinic patients suffering mucosal infections 
emphasizes the urgent need to develop a vaccine targeted at mucosal-associated 
lymphoid tissues. To achieve this goal, the passage of vaccine antigens into or across 
the epithelial barrier is the first step in the complex sequences of events that lead to 
mucosal, and potentially, systemic immunity.  Mucosal and system immune 
responses can be more efficiently achieved by directly applying antigens of vaccines 
onto mucosal surfaces (209). The close associations among epithelial, immune 
effector and antigen presenting cells create an efficient mechanism for sampling 
lumenal vaccine antigens. This ideal sampling should trigger the induction of mucosal 
immunity and result in protection of mucosal surfaces. However, epithelial 
monolayers lining the mucosal surfaces are impervious to macromolecule diffusion, 
due to the presence of intercellular tight junctions at the apical poles (185). In this 
way, mucosal barriers insulate cross-talk between lumenal vaccine antigens and the 
immune effectors cells within the laminar propria, resulting in the exclusion of 
vaccine antigens from transport across the epithelial barrier or from taking up for 
processing and presentation to subjacent lymphoid tissue within the epithelium, 
lamina propria and draining lymph nodes. Different approaches have been taken in an 
exploratory way, such as targeting mucosal vaccines onto the specially differentiated 




relatively rare (only accounting for 0.1% of epithelial cells) and sparsely scattered, 
leading to the less efficient delivery of antigens. Therefore, it is necessary to explore 
novel pathways to efficiently deliver vaccine antigens across mucosal barriers.  
 
The neonatal Fc receptor for IgG (FcRn) was first identified in the intestinal 
epithelial cells of a suckling rodent, where it is expressed at high level. FcRn transfers 
maternal IgG across the polarized placental and/or intestinal epithelial cells (124), 
which allows newborns to obtain maternal IgG against antigens encountered by the 
mother before they develop their own immune system. However, its functional 
expression in a variety of cells and tissues, including epithelial cells lining mucosal 
surfaces, has recently been identified in adult animal and humans (118). Further work 
has showed that FcRn is also responsible for shuttling IgG antibodies across mucosal 
surfaces. In addition to its function as a transporter, FcRn protects IgG by extending 
their life span (124, 141). FcRn binds IgG isotypes in a pH-dependent manner, 
binding IgG at acidic pH (6.0-6.5) and releases IgG at neutral or higher pH (124). 
Amino acid residues, I253, H310, and H433 located at the interface between CH2 and 
CH3 domains of IgG, are of particularly functional significance to this pH-dependent 
binding (124). In the majority of cell types, FcRn resides primarily in the early acidic 
endosomal vesicles with limited cell surface expression. In early endosome, FcRn 
binds IgG that enters cell by pinocytosis or endocytosis. Subsequently, FcRn recycles 
IgG back to the cell surface in nonpolarized cells or transcytoses IgG to the opposite 
surface in polarized epithelial cells. The near neutral pH of extracellular environment 




moves to lysosomes where it undergoes degradation.  
 
Observations on IgG transport within mucosal epithelia by FcRn imply that 
FcRn may transport antigen, if fused with the IgG Fc, across the mucosal barrier. 
Several lines of evidence suggest that this pathway for direct shuttling of Fc-antigen 
may be feasible. For example, in the rodent, IgG-mediated immune complexes can be 
transported from the gut lumen (149). Therefore, FcRn-mediated mucosal vaccine 
delivery, if possible, might allow the host to specifically sample an Fc-fused subunit 
vaccine in the mucosal lumen, followed by transport across the mucosal epithelial 
barrier. Such an idea has never been tested for delivering a subunit vaccine across 
mucosal barrier against a particular pathogen. Herpes simplex virus type-2 (HSV-2) 
causes sexually-transmitted disease and the primary site of HSV-2 infection is the 
mucosa of the genital tract. The development of HSV-2 subunit vaccines is focusing 
on their major envelope glycoproteins, because of their key roles in the early steps of 
viral infection and their being major targets for both humoral and cellular immunity. 
Of these glycoproteins, gD is proposed as a principal vaccine candidate, since gD 
induces a more consistent and stronger cellular immune response and gD-specific 
antibody has the highest complement independent neutralization titer (242). In this 
study, we were elected to determine the ability of FcRn to deliver the model antigen, 
HSV-2 gD-Fc fusion protein, across the respiratory mucosal barrier to probe immune 
responses to this mucosal immunization and to define protective immune responses 
and mechanisms against mucosally-administered virulent HSV-2 challenge. We 




specific antibody responses in both serum and mucosal secretions and maintaining 
high levels of protective immune responses for at least six months in mice. The 
memory response was domonstrated by antibody secreting plasma cells, memory B 
cells, and IFN-γ and IL-2 producing T cells with antigen-specific proliferative 
potential and superior cytokine production profiles. These results are the first to 
demonstrate that the FcRn-IgG transcellular pathway may represent a novel mucosal 
subunit vaccine delivery against mucosal pathogens in humans.  
 
MATERIALS AND METHODS 
 
Cells, antibodies, and virus 
Chinese Hamster Ovary cells were grown in DMEM with 10% FCS (Gibcol), 
when necessary complemented with 400 μg/ml of G418. Inner Medullary Collecting 
Duct (IMCD) cell line expressing rat FcRn was gift from Dr. Neil Simister in the 
Brandies University, grown and maintained in DMEM with 10% FCS. Splenocyte 
suspensions or bone marrow cells (5x105/ml) were incubated overnight at 37°C and 
5% CO2 in a humidified incubator in complete medium (RPMI 1640 medium with 
10% (vol/vol) FCS, penicillin (100 units/ml), streptomycin (100 μg/ml) and 2-
mercaptoethanol (50 μM; Sigma). Herpes Simplex Virus-2 186 (HSV-2) strain was 
from Dr. Lawrence Stanberry (Columbia University, New York, NY) and virus stocks 
were prepared by infection of Vero cell monolayers at a multiplicity of infection of 
0.01. All epithelial and CHO cells were maintained in DMEM complete medium 




serum, 2 mM L-glutamine, nonessential amino acids, and penicillin (0.1 μg/ml)/ 
streptomycin (0.292 μg/ml) in a humidified atmosphere of 5% CO2 at 37°C. 
 
Antibody specific for mouse FcRn was prepared as previously descirbed 
(247). HRP-conjugated donkey anti-rabbit or rabbit anti-mouse Ab was purchased 
from Pierce, purified mouse IgG and chicken IgY was from Rockland Laboratories, 
and HRP-conjugated goat anti-mouse IgG1, IgG2a and IgG3 were from Southern 
Biotech. All DNA modifying enzymes were purchased from New England Biolab. 
Purified HSV-2 glycoprotein D was purchased from Meridian Life Science. 
 
Expression of gD-Fc Fusion Proteins 
        cDNA encoding the extracellular domain of HSV-2 gD (26aa-340aa) was 
amplified by PCR from a plasmid provided by Dr. Patricia G. Spear (Northwestern 
University) using the forward primer, 5’-
CCCAAGCTTAAAATGGGGCGTTTGACCTCCGGC-3’, and backward primer  
,5’-
AGATCCCGAGCCACCTCCTCCGGACCCACCCCCGCCTGATCCGCCCGGGT
TGGCTGG-3’ to introduce a COOH-terminal extension with fourteen codons for 
glycine and serine residues (GSSGGGSSGGSSS). The Fc-fragment of mouse IgG2a 
containing hinge, CH2 and CH3 domains was amplified from the OKT3 hybridoma. 
The mutant Fc (HQ310 and HN433), unable to bind mouse FcRn, was made by 
oligonucleotide site-directed mutagenesis (Clontech). To construct a nonlytic Fc 




binding motif Glu318, Lys320, Lys322 with Ala residues. Fusions were then performed 
in PCR-based gene assembly approach by mixing the cDNA for gD and the Fc 
fragment. All these DNA fragments were ligated into the pCDNA3 vector. Each 
construct was verified by DNA sequencing.  
            
        The plasmid containing the chimeric gD-Fc fragment was transfected into 
Chinese hamster ovary (CHO) cells. G418-resistant clones were selected for secretion 
of gD-Fc. SDS-PAGE and Western blot were performed to assess the recombinant 
fusion proteins in serum-free medium (SFM, Invitrogen). The highest secreting 
clones were screened. Recombinant proteins were purified from CHO cell 
supernatants by affinity chromatography using Protein A Sepharose 4 Fast Flow 
(Amersham Pharmacia Biotech) or goat anti-mouse IgG affinity column (Rockland). 
Protein concentration was measured with Brafold Kit (Pierec) using mouse IgG2a as 
standard.  
 
In vitro and in vivo transcytosis 
          The in vitro IgG transport was performed as a modification from previously-
described methods (147). IMCD cells expressing rat FcRn were grown onto transwell 
filter inserts (Corning Costar) to form a monolayer exhibiting transepithelial electrical 
resistances (TER, 400 .cm2). TER was measured using a tissue-resistance 
measurement equipped with planar electrodes (World Precision Instruments, 
Sarasota, FL, USA). Monolayers were equilibrated in Hanks’ balanced salt solution. 




incubated with DMEM medium supplied with or without 1mg/ml of mouse IgG or 
chicken IgY as competitors for 2 hr at 37°C degree. Transported proteins were 
sampled from the basolateral chamber and analyzed by reducing SDS-PAGE and 
Western blot-ECL. For in vivo transport, the biotinylated 20 μg of fusion proteins or 
gD alone in 20 μl of PBS were intranasally (i.n.) administered into the mice that were 
anethesitized with isoflourane. 8 hr later or at indicated time points, transported 
proteins in sera were determined by ELISA. NIH Image software (National Institutes 
of Health, Bethesda, MD) was used to determine relative band intensities of a blot.   
 
Mice immunization and virus challenge 
Female inbred C57BL/6 mice aged 6 to 8 weeks were purchased from the 
Charles River. The B6.129x1-Fcrgttm1Dcr (FcRn-/-) were from the Jackson 
Laboratory. All mice were housed in the animal resources facility at the University of 
Maryland. All animal studies were reviewed and approved by the Institutional Animal 
Care and Use Committee. To overcome the possible mucosal immune tolerance 
(243), all proteins and PBS were loaded with immunostimulatory DNA rich in CG 
motifs (CpG). Groups of 5 mice were intranasally immunized with 20 µl of 20 μg 
gD-wtFc, gD-mutFc, or recombinant gD alone in combination with 20 μg CpG 
ODN1826 (5′-TCCATGACGTTCCTGACGTT-3′) (Invivogen) per immunization  at 
weeks 0 and 2 under an anesthesia condition with isofluorane. One group of 5 mice 
was mock-immunized with PBS following the same schedule. Mice were kept on 
their backs under the anesthesia to allow the inoculum to be taken up. 




        Mice were inoculated with viruses intravaginally as described previously (244). 
Briefly, 7 days prior to inoculation, mice were treated with 3 mg of 
medroxyprogesterone acetate (Depo-Provera, Pfizer) subcutaneously in a 10-day 
period. Hormonal pretreatment was necessary to induce susceptibility of mice to 
genital HSV-2 inoculation, which may reflect thinning of the genital epithelium or 
induction of the HSV entry receptor, nectin-1, on vaginal epithelial cells. Avertin 
(Sigma) anesthetized mice were infected intravaginally with 1×104 pfu of wild-type 
HSV-2 strain 186 in a total volume of 20 μl. Mice were kept on their backs under the 
influence of anesthesia for 45 min to allow infection. Mice were monitored for 14 
days for the pathology and death. For virus titration, virus were inoculated into Vero 
cells, incubate for 45 minutes at 37°C. After washing, 1% methcellulose in DMEM 
containing 2% FCS were added to overlay the cells. The cells were cultured for 
additional 3 days, and the overlay was removed and fixed with 3.7% formaldehyde 
for 1 hr, then staining with 1% crystal violet.  
 
Preparation of single-cell suspensions from lymph nodes, spleen, lung, and 
vaginal tissues 
        Spleens and lymph nodes were made into single-cell suspensions by passage 
through a sterile mesh screen. Cells were resuspended in Hanks’ balanced salt 
solution (HBSS) and counted by trypan blue dye exclusion. For each experiment, 
LNC and spleens were generally pooled from 3 mice. For the preparation of single-
cell suspension from lung, mice were administered with 400 ul of Avertin through i.p. 




with blades, and incubated with HBSS (Hyclone) containing 2.5 mM Hepes and 1.3 
mM EDTA at 37°C for 30 minutes, followed by treatment at 37°C for 1 hr with 2.5 
mg/ml collengase D (Roche) in RPMI 1640 medium containing 5% FBS. A single-
cell suspension was prepared after RBC lysis. The resulting cells were filtered 
through a 70-um cell strainer (BD) and used for FACS analysis.  
  
        For isolation of vaginal lymphocytes, the vagina was excised, the cervix was 
removed, and the remaining vaginal tissue was cut longitudinally and minced with a 
sterile scalpel in complete RPMI 1640 culture medium. Minced tissues (epithelium 
and lamina propria) were digested in complete medium with sterile 0.25% 
collagenase type IV (Sigma Chemical Co., St. Louis, Mo.). Digestion was 
accomplished with shaking incubation at 37°C for 30 min. After digestion, tissues 
and cells were filtered through a sterile gauze mesh and washed with RPMI 1640 
medium, and additional tissue debris was excluded by slow-speed centrifugation for 1 
min. Cells were collected from the supernatant by centrifugation, resuspended in 
HBSS, and counted by trypan blue dye exclusion.  
 
Flow cytometry  
        Single cell suspensions from the spleen, lung or vaginal tissues were collected 
and cells were spun down. Erythrocytes were then lysed in 0.14 M NH4Cl, 0.017 M 
Tris-HCl at pH 7.2 on ice for 10 min. Cells were preincubated with an Fc block (mAb 
to CD16–CD32, 2.4G2, PharMingen, San Diego, CA) and washed in FACS buffer 




specific antibody (0.25 μg/106 cells/100 μl) directly conjugated to fluorsecein 
isothiocyante (FITC), phycoerythrin (PE), washed, and analyzed using a FACScan 
(Becton Dickinson, Mountain View, CA). The mAbs (PharMingen) we used were 
anti-CD3ε, 500A2; anti-CD4, RM4- 5; anti-CD8, 53-6.7; anti-IFN-γ, XMG1.2, anti-
B220, RA3-6B2, FAS, Jo2, PNA (Sigma). Purified HSV-2 gD proteins were labeled 
with Alexa Fluro647 protein labeling kit (Invitrogen) according to the manufacture’s 
instruction. Cells incubated with rat IgG2a, rat IgG2b, or hamster IgG isotype control 
antibodies were used to determine the background fluorescence. The isotype control 
antibodies included in each experiment were considered the true baseline 
fluorescence used to evaluate and illustrate the results for the cell-specific antigen 
markers. Cells were washed in FACS buffer and analyzed using a FACSAire and 
FlowJo software (Becton Dickinson, Mountain View, CA). 
 
T cell proliferation 
        Single cell suspensions from mouse spleen were suspended in RPM-1640 with 
1% FCS, 2.5mM Hepes at 107/ml. Carboxyfluorescein diacetate succinimidyl ester 
(CFSE, 5mM in stock, Invitrogen) was 10-fold diluted with PBS, 4 μl of diluted 
CFSE was then added into 107/ml cells for a 2 μM final concentration. The reaction 
was incubated for 10 min at 37°C. The 1 ml cold FCS was added incubated on ice for 
5 min to stop the reaction. The cells were washed twice with RPMI-1640 with 10% 
FCS. The 5x105 labeled cells were plated into 96 well plates in 200 μl of medium and 
cultured for 4 days. The cells were then harvested and subjected to flow cytometry 





Intracellular cytokine staining  
        Intracellular IFN-γ production by primed CD4+ and CD8+ T cells was evaluated 
using bulk splenocytes or isolated lung or vagina infiltrating lymphocytes incubated 
for 8 hr with 25 μg//ml of the purified gD protein or medium alone. Cells were then 
cultured for another 10 hr in the presence of brefeldin A (Sigma, St. Louis, MO). 
Then cells were washed and incubated with anti-CD16/CD32 antibody to block Fcγ 
receptors, and stained with anti–mouse CD4, CD8, and CD3 antibodies for 15 min at 
4°C. After fixation and membrane penetration with Cytofix/Cytoperm Plus (BD 
Biosciences), cells were stained for intracellular IFN-γ for 30 min on ice. All mAbs 
were purchased from BD Biosciences. Cells were washed three times, resuspended in 
FACS buffer, and analyzed by flow cytometry. Data was collected using FACSAire 
and analyzed using FlowJo software (Tree Star). 
 
Enzyme-linked immunosorbent assay (ELISA), plasma cell ELISPOT, and 
neutralization test 
          For the detection of gD-specific antibodies in serum, bronchial lavage and 
vagina fluid of mice, high-binding ELISA plates (Maxisorp, Nunc) were coated with 
5 μg/ml of recombinant gD protein in PBS and incubated overnight at 4 °C. Plates 
were then washed three times with PBS-Tween 20 0.02% and blocked with PBS-BSA 
1% for 1 h at room temperature. Serial dilutions of the samples or controls in PBS-
BSA 0.25% were incubated for 2 h at room temperature and visualized with rabbit 




anti–mouse subclass-specific antibodies (1:5000; SouthernBiotech), followed by 
colorimetric assay using tetramethyl benzidine. OD450 was measured using a Victor 
III microplate reader (Perkin Elmer). Titers represent the highest dilution of serum 
showing an OD450 having 2 fold of control. Neutralizing antibodies were measured by 
a standard virus neutralization assay. Sera were heat-inactivated, diluted 10-fold, then 
in twofold steps in MEM with 2% FBS. Fifty PFU of HSV-2 per well were added and 
incubated at 37°C for 1 hr. Methylcellulose (0.8%) in DMEM  containg 2% FCS 
were added and incubated for 72 hr at 37°C. The titers were expressed as the 
reciprocal of twofold serial dilution decreasing the half of plaque number of control 
group. Each assay was done in triplicate.  
      
        For measuring anti-gD antibody-producing plasma cells, the 96-well ELISPOT 
plates (MultiscreenTM HTS HA; Millipore) were coated with gD (5 μg/ml) and 
blocked with RPMI 5% FCS (Invitrogen) for 90 min at 37°C and 5% CO2. Serial 
dilutions of bone marrow single-cell suspensions were prepared in RPMI 5% and 
incubated in the coated wells for 24 hours at 37°C in 5% CO2. Cells were removed, 
and plates were washed with PBS-T for 5 times, then incubated with biotin labeled 
goat anti–mouse IgG-specific antibody (1:1500; Sigma) for 2 hours. After washing 
with PBS, the avidin conjugated to horseradish peroxidase (1:2,000; Vector 
Laboratories) was added and incubated for 1 hour, followed by substrate from the 
AEC kit (BD Biosciences). Spots were counted with Elispot Reader and analyzed 








        Immunofluorescence was performed based on methods previously described 
(245). Briefly, frozen serial sections of the lung were cold-fixed in 3.7% 
paraformaldehyde (Sigma) in PBS for 30 min at 4°C and quenched with glycine for 
10 min and stained with anti-PNA (germinal centers, red) and anti-B220 (B cells, 
green), followed by Alexa 555 or 488 Fluro-conjagated IgG of the corresponding 
species. After each step, cells were washed at least three times with 0.1% Tween-20 
in PBS. Coverslips were mounted on slides with ProLongTM antifade kit 
(Molecular Probes) and examined using a Zeiss LSM 510 confocal fluorescence 
microscopy. Images were manipulated in Adobe Photoshop 7.0. 
 
Western blot and SDS-PAGE gel electrophoresis 
    The proteins in the medium or extracted from lung tissue were resolved on a 
12% SDS-PAGE gel under a reducing or non-reducing condition. Proteins were 
electro transferred onto a nitrocellulose membrane (Schleicher & Schuell). The 
membranes were blocked with 5% non-fat milk, probed separately with anti-gD, anti-
IgG Fc Ab or anti-mouse FcRn for 1 hr, and followed by incubation with HRP-
conjugated rabbit anti-mouse or donkey anti-rabbit Ab. All blocking, incubation, and 
washing were performed in PBST solution (PBS and 0.05% Tween 20). Proteins were 





Passive transfer of immune sera 
        Sera were collected weekly from the mice 4 weeks after immunization, then 
pooled , heat inactivated at 56°C  for 30 minutes and stored frozen at -80°C until use. 
Mice received a single intraperitoneal (i.p.) injection of 0.3 ml immune sera 24 hours 
prior to challenge to allow distribution and equilibration of antibody to all tissues 
prior to virus inoculation. Mice were challenged intravaginally with 1 X 104 PFU 
HSV-2 186 strain.  
 
Statistics 
        To compare survival curve, Kaplan-Meier log-rank analyses were used. Ab 
titers, concentration of gD in serum, cytokine concentration and virus titers were 
assessed by using the unpaired two-tailed t test. GraphPad Prism 5 provided the 
software for the statistical analysis.  
RESULTS 
Production of HSV-2 gD-Fc fusion proteins 
             To determine whether antigens targeted to FcRn in vivo produce antibody and 
cellular immune responses, we generated a fusion protein HSV-2 gD-wtFc by cloning 
the extracellular domain of gD in frame with the carboxyl terminus of the heavy chain 
of the mouse IgG2a antibody (Figure 3.1A). We elected to use mouse IgG2a Fc 
fragment since mouse IgG2a, but not IgG1, Fc is capable of binding mouse FcγRI. 




generating a gD-mutFc. In this mutant, point mutations (HQ310 and HN431) were 
introduced into the Fc-domain known to inhibit binding to FcRn (122). In all these 
constructs, the constant regions of the mouse IgG2a were also modified to remove 
complement C1q-binding motif (246) to produce nonlytic fusion proteins.  
 
The fusion proteins were produced by CHO transfection with the gD-Fc 
constructs. The secreted gD-Fc fusion proteins formed monomers under reducing 
conditions, but exhibited as disulfide-linked homodimers under non-reducing 
conditions in Western blot, using both the affinity-purified anti-gD and anti-Fc 
antibodies (Figure 3.1B). A functional test of the Fc-domain was confirmed in vitro 
by immunoprecipitation with Staphylococcal protein A beads for gD-wtFc. It has 
been shown that protein A makes contact with overlapping amino acids of IgG Fc for 
binding to the FcRn (118, 124). As expected, protein A effectively to fusion protein. 
Therefore, this suggests the Fc portion of IgG on the gD-wtFc maintains all structures 
necessary for binding FcRn.  
 
Transcytosis of gD-wtFc fusion proteins  
In nature, FcRn transports maternal IgG across the placenta and intestine with 
a high affinity (118). Two criteria were applied to demonstrate FcRn-mediated 
transport of gD-wtFc. First, an IMCD-FcRn cell line was used to transport gD-wtFc 














Figure 3.1. Design and characterization of HSV-2 gD fused to IgG Fc fragment.  
(A). Schematic illustration for the genetic fusion of HSV-2 gD and murine Fcγ2a cDNA to 
create a gD-Fc fusion gene. Mutations were made in the CH2 domain of Fcγ2a fragment by 
using site-directed mutagenesis to replace Glu318, Lys320, and Lys322 with Ala residues to 
remove complement C1 q binding site, and His 310 and His 433 with Ala residues to 
eliminate FcRn binding sites.  
(B). The gD-Fc fusion proteins were secreted by CHO cells. The gD-Fc was recognized by 
either rabbit anti-mouse IgG (top panel) or a mAb anti-gD. The fusion protein was exhibited 
as a dimer under non-reducing (NR) or a monomer under reducing (R) condition.  
(C). Transport of gD-wtFc fusion proteins in rat IMCD-FcRn cell lines. IMCD-FcRn cells 
were plated onto 24-mm transwells and grown for 3-6 days to allow a polarized monolayer 
with resistance greater than 300 Ώ cm2 to form. The purified gD-wtFc (50μg/ml) was applied 
to the apical reservoir and allowed for transcytosis for 2 hr. The proteins were collected from 
the basolateral reservoir and blotted with anti-gD antibody under reducing condition. The gD-
wtFc fusion protein (lane 3) was transported from the apical to basolateral surface. The 
transport was inhibited by an excessive amount of mouse IgG (lane 2), but not by chicken 
IgY (lane 3).Wt: wild-type.  
(D). Expression of mouse FcRn in the epithelial cells of mouse trachea and lung. The 
epithelial cell lysates from trachea, lung, intestine, and liver of 6 week C57B6/L mice was 
blotted with anti-mouse FcRn and anti-tubulin antibody. Molecular weight markers are 
indicated in kDa.  
(E). Purified, gD, gD-wtFc and gD-mutFc proteins (20 μg) were intranasally inoculated into 
wild-type and FcRn KO mice as indicated. 8 hr later, the mouse sera were collected, the gD 
or gD-Fc protein concentration was measured by ELISA. Inoculation conditions are 
displayed at the bottom of the panel. Star (**) denotes p<0.01. 
(F). Persistence of the transported gD-Fc fusion protein in the mouse serum. Proteins (20 μg) 
were intranasally inoculated into wild-type and FcRn KO mice as indicated. The mouse sera 
were collected and the gD or gD-Fc protein concentrations were measured by ELISA as 














        The IMCD cells expressing rat FcRn have been shown to specifically and 
saturably transport murine IgG when grown in transwell (147). FcRn-dependent 
transcytosis of gD-wtFc in either purified or crude medium to the apical reservoir was 
detected by Western blotting of material collected from the basolateral reservoir 
under reducing conditions. The gD-wtFc fusion protein (Figure 3.1C, lane 3) was 
transported from the apical to basolateral surface. The transport was inhibited by an 
excessive amount of rodent IgG (lane 2), but not by chicken IgY (lane 1). Chicken 
IgY does not bind FcRn. Lane 4, representing gD-wtFc, was used as a positive 
control.  For in vivo transcytosis, we first determine the expression of FcRn in the 
epithelial cells of trachea, lung, and liver by Western blot (Figure 3.1D). It was 
revealed that the whole respiratory tract expressed FcRn. Given that FcRn higly 
expressed by respiratory epithelial cells (247), we wanted to see whether FcRn can 
deliver the gD-Fc across mucosal barrier and reach the sera after i.n. inoculation. To 
this end, 20 μg of the gD-wtFc, gD-mutFc, or gD proteins were administered i.n. and 
measured 8 hr later using ELISA. As shown in Fig. 1E, gD-wtFc could readily be 
detected in sera of wt mice but not FcRn KO animals (Figure 3.1E). In addition, 
smaller amounts of gD-mutFc or gD alone was detected in the sera of wt mice in 
comparison with that of the gD-wtFc, indicating that i.n. administered gD-wtFc 
efficiently crosses the respiratory barrier and reaches the sera. Furthermore, FcRn 
functions in protecting IgG from degradation (124). For this reason, we measured the 
persistence of gD-Fc fusion proteins in the sera of inoculated mice. The results 
showed that the transported gD-wtFc in the sera of wild type mice persisted about 5 




rodent FcRn can transport the gD-wtFc fusion proteins in the polarized epithelial cell 
lines and in the respiratory tract of mice, further suggesting gD-wtFc maintains 
structural integrity and biological function for interacting with FcRn. In addition, 
inactivating complement C1q binding motif has no effect on the FcRn binding 
potency of the fusion proteins. 
 
Protection against HSV-2 challenge 
To test the theory that FcRn functions as a receptor to transport subunit 
vaccines across mucosal surfaces in adult mice, we i.n. immunized mice with gD-Fc 
or gD proteins and boosted them similarly after 2 weeks. To determine if immunity to 
FcRn-mediated mucosal vaccine delivery leads to protection, we challenged the mice 
with a lethal dose of 1×104 pfu of HSV-2 186 strain 30 days following the boost. 
Mice immunized with the gD-wtFc were protected from a lethal challenge and 
showed 100% survival (Figure 3.2.A). The gD-wtFc immunized wt mice showed 
significantly higher survival compared to the gD-mutFc group, gD-wtFc-immunized 
FcRn KO group, and gD immunize group (Figure 3.2A). As expected, PBS control 
mice succumbed to lethal infection. Additionally, viral titers measured in the vaginal 
washs taken after infection showed that the gD-wtFc immunized mice had completely 
controlled viral titers by day 4 after challenge compared to other groups (Figure 
3.2B). Overall these results demonstrate that i.n. administration of gD-Fc antigens 







Figure 3.2. FcRn-targeted mucosal vaccination provides protective immunity to 
intravaginal challenge with virulent HSV-2 186. Groups of five mice were immunized i.n. 
with 20 μg gD-wtFc, gD-mutFc, or gD alone. Initial immunization conditions were as 
follows: gD-wtFc in wt mice ( ), gD-wtFc in FcRn KO mice ( ), gD-mutFc in wt mice ( ), 
gD alone (*), and PBS (x). Mice received boost, and after 1 month, they were challenged 
intravaginally with 1×104 pfu of HSV-2 strain 186.  
(A) Mean survival following genital HSV-2 challenge. Percentage of mice from protection on 
the indicated days calculated as the number of mice survival divided by the number of mice 
in each group. Three weeks following immunization, mice were challenged intravaginally 
with 1×104 pfu of HSV-2.  
(B) Mean of viral titers following HSV-2 challenge. Virus titer was measured in vaginal 
washes by taking vaginal swabs on the indicated days after HSV-2 inoculation. Viral titers 











Strong anti-gD antibody responses after immunization with FcRn-targeted gD-
wtFc 
           To further elucidate the protective immune mechanism, we first analyzed the 
humoral immunity elicited by gD-Fc fusion protein adjuvanted with CpG. HSV-2 gD 
has major and minor immunodominant serological epitopes (248, 249). To determine 
whether antigen targeting to FcRn by gD-wtFc elicits antibodies to potential vaccine 
target antigen gD, we measured antibody immune responses to the gD antigen.  
Immune responses in vaccinated animals, including adjuvant controls and naive mice, 
were assessed at various time points up to 56 days after the primary immunization by 
measuring the gD-specific IgG. Mice were bled at indicated days, and the IgG 
antibody titers in sera were measured by ELISA against the gD. On each post-
vaccination, gD antibody displayed similar kinetics among primed groups. However, 
significantly higher titers of IgG were seen in the gD-wtFc immunized mice when 
compared with other groups (Figure 3.3A). To further characterize the antibody 
responses, we determined the subclass specificity of the anti-gD IgG response. 
Immunization with the gD-wtFc elicited antibodies with mainly restricted to the 
IgG2a subclass (Figure 3.3B). We conclude that immunization by targeting antigens 
to FcRn together with a CpG adjuvant produces strong humoral immune responses to 
HSV-2 gD. 
 
To examine whether the sera from the immunized mice have the neutralizing 
activity, we performed in vitro neutralization test. The sera from the gD-Fc 




(Figure 3.3C). To further examine the protection provided by the serum antibody in 
vivo, groups of five mice received 0.3 ml the immunized sera 24 hours prior to ivag 
HSV-2 challenge. B6 mice receiving the sera from the gD-wtFc immunized mice 
were significantly protected compared to PBS-immunized animals and other groups 
respectively, Figure3.3D). Administration of the sera from the gD-wtFc immunized 
mice to B6 mice resulted in significantly lower HSV-2 titers in the vaginal epithelium 
on day 2 after inoculation compared to PBS-treated controls.  
 
Strong T cell responses to FcRn targeted mucosal immunization 
            Naive C57BL/6 mice were immunized with 20 µg gD-wtFc or gD-mutFc in 
the presence of a DC maturation stimulus CpG because the latter is considered to be 
effective in producing T cell help for antibody responses. 4 days after the boosting, 
spleen cells isolated from immunized mice were pulsed with purified gD, and the 
frequency of IFN-γ+ Τ cells  was measured by flow cytometry. We detected 
significant number of IFN-γ secreting CD4+ (Figure 3.4A, upper panel) and CD8+ 
(Figure 3.4A, bottom panel) T cells in response to gD in the group immunized with 
gD-wtFc, but rarely in any of the other groups, including mice immunized with gD-
mutFc. In the gD-wtFc immunized mice, about 0.88 % of the CD4+ and 1.6% of the 
CD8  T cells became responsive to stimulation. Targeting the gD-wtFc via FcRn was 
more effective at initiating IFN-γ–producing CD4+ and CD8+ T cell immunity (Figure 
3.4A) than control proteins. The cytokine responses were dominated by T cells with 
cytokine IFN-γ and IL-2 and a lack of the IL-4 production when splenocytes were 





Figure 3.3. FcRn-targeted mucosal vaccination induces enhanced antibody responses. 
Antigen-specific antibody titers were determined for each mouse in a group (n = 3) from 
serum harvested at indicated days post vaccination.  
(A+B). Measurement of anti-HSV-2 gD-specific IgG antibody titers in serum before and after 
the boost immunization (mice was boost immunized 14 days after primary immunization). 
Blood samples were taken from mice by tail bleeding. HSV-2 gD-specific IgG antibody as 
indicated days (A) or IgG isotype 21 days post boost was measured in serum by ELISA. 
Immunization conditions are displayed at the right. The curves represent mean values for 
each group (±S.E.M.). (C). Test of neutralizing activity in the immunized sera. Sera were 
heat-inactivated, diluted 10-fold, then in twofold steps in MEM with 2% FBS. Fifty PFU of 
HSV-2 were added and incubated at 37°C heat inactivated serum for 1 hr. Finally, Vero cells 
were added and incubated for 48 hr at 37°C. The titers were expressed as the reciprocal of 
twofold serial dilution reducing the half of the CPE compared to control serum. Each assay 
was done in triplicate. Star (*) denotes p<0.01. 
(D). Survival of mice following passive transfer of immunized mouse sera. Groups of five 
mice received 0.3 ml of immunized sera prior to ivag inoculation with 1 X 104 PFU HSV-2. 
24 hours following transfer, mice were challenged intravaginally with 1×104 pfu of HSV-2. 








We conclude that immunization with gD-wtFc fusion protein induces strong CD4+ 
and CD8+ T cell responses, whereas the immunization with gD-mutFc or the gD-wtFc 
immunized wt mice do not. 
 
Induction of local mucosal immune responses 
The mediastinal lymph nodes (MLN) drain the lung and are usually the site 
where mucosal immune responses are initiated against antigens reaching the lung. At 
first, to ascertain the ability of the FcRn-targeted mucosal delivery of the gD-wtFc 
generates the germinal center (GC) in the MLN, it was removed 10 days later after 
the boost. The GC is antigen-specific as characterized by the presence of peanut 
agglutinin (PNA)-positive areas and Fas apoptotic death receptor is highly expressed 
in activated and GC B cells (250, 251). Cells from the MLN were gated on B220+ 
cells and stained for the presence of PNA- and Fas-positive B cells. As shown in 
Figure 3.5A, the gD-wtFc immunization efficiently induced GC, displaying much 
higher frequency of FAS+PNA+B220+ B cells than all other groups. Therefore, we 
conclude that antigenic stimulation induces the activation of B cells to form GC in 
draining MLN by FcRn-targeted mucosal vaccine delivery. 
 
It has been previously shown that vaccine or antigens can induce bronchus-
associated lymphoid tissue (iBALT), which is very similar to germinal centers in 







Figure 3.4. FcRn-targeted mucosal vaccination enhances HSV-2 gD–specific T cell 
responses. 20 μg of fusion protein or gD with 20 μg CpG were administered i.n. into wild-
type or FcRn KO mice.14 days later, mice were booster immunized. Spleenocytes were 
harvested 4 days post boost. The percentage of IFN-γ+ T cells in gated CD3+ splenic T cells 
were assessed after co-culture with 10μg/ml of gD 
(A) IFN-γ production by CD4+ and CD8+ T cells is shown as dot plots of gated CD3+ T cells 
stained for CD4 and CD8 and intracellular IFN-γ in the spleen of the immunized mice. Spleen 
cells from immunized mice were stimulated for 24 hr with purified gD or medium control. 
Lymphocytes were gated by forward and side scatter and T cells labeled with anti-CD3 and 
identified by their respective surface markers CD4 and CD8. Immunization conditions are 
displayed on the top. Number in each quadrant represents the percentage of IFN-γ+ CD3+ 
CD4+ (top panels) or IFN-γ+ CD3+ CD8+ (bottom panels) T cells 
 (B) Cytokine secretions from re-stimulated spleen T cells. Spleenocytes from immunized 
mice were restimulated in vitro specifically with different multiplicity of infection (MOI) of 
inactivated HSV-2 virus as indicated.  Cytokines IFN-γ, IL-2, and IL-4 secreted into the 
culture supernatant were detected by ELISA and are presented as picograms/ml of culture 
supernatant. Data are representative of three experiments with three mice pooled in each 







        To address the possibility of iBALT being induced by FcRn targeted 
immunization, lungs of i.n. immunized animals were analyzed immunohistologically 
by confocal microscope. As shown in Figure 3.5B, such germinal center-like structure 
could be steadily detected in the lung of the gD-wtFc immunized mice, but it was 
absent from the gD-mutFc, gD alone, or PBS immunized mice. The gD-wtFc 
immunized FcRn KO mice exhibited a low intensity staining in the lung, but it did not 
reach the significant difference.  This indicates that FcRn targeted gD-wtFc delivery 
can induce strong mucosal immunity.  
 
Antibodies, in particular sIgA and IgG, represent a first line of defense on 
mucosal surfaces. In order to assess the ability of the FcRn-targeted immunization to 
induce gD-specific antibody in mucosal secretions, the bronchial alveolar lavage 
(BAL) were collected two weeks following the boost and analyzed for gD-specific 
IgG and IgA by ELISA. In order to determine if the antibody responses induced by 
i.n. immunization were disseminated to distant mucosal sites, vaginal washes were 
also taken and subjected to antibody analysis. Significantly increased levels of gD-
specific IgG in the lung lavages (Fig. 3.5C, middle panel) and vaginal washes (Fig. 
3.5C, right panel) were observed in the gD-wtFc immunized group. Low level of gD-
specific IgG was detected in the lung lavages and vaginal washings of mice 
immunized with the gD/Fc/mut or gD alone. Only wt but not FcRn KO mice that 
received the gD-Fc i.n. had high levels of gD-specific IgG antibodies in BAL and 
vaginal washings (p <0.01, Figure 3.5C), suggesting the appearances of mucosal IgG 




both BAL and vaginal washings, although we were able to detect significant amount 
of IgA in nasal washings (Figure 3.5A, left panel).  
  
        To further show whether FcRn targeted mucosal delivery vaccine can induce T 
cell immune responses in the lung and vaginal tissues, 4 days after the boosting, lung 
lymphocytes isolated from the immunized mice were pulsed with purified gD, and 
IFN-γ secreting cells were measured by flow cytometry. We detected significant 
number of IFN-γ secreting CD4+ (Figure 3.5D, upper panel) and CD8+ (Figure 3.5D, 
bottom panel) T cells in response to gD in the group immunized with gD-wtFc in 
comparison with other groups, including mice immunized with gD-mutFc or FcRn 
KO mice immunized with the gD-wtFc. Similarly, vaginal lymphocytes isolated from 
the challenged mice displayed significant number of IFN-γ secreting CD4+ (Figure 
3.5E, left panel) and CD8+ (Figure 3.5E, right panel) T cells in the mice immunized 
with gD-wtFc in comparison with other groups. We conclude that immunization with 
gD-wtFc fusion protein induces strong IFN-γ producing CD4+ and CD8+ T cell 
responses at the mucosal sites, whereas the immunization with gD-mutFc does not. 
 
FcRn targeted mucosal immunization elicits long-lived humoral immune 
responses  
                A hallmark of humoral immune responses is the activation of GC B cells 
leading to the further differentiation into memory B cells and long-lived plasma cells 
(252). At first, to ensure the ability of the FcRn-targeted mucosal vaccine generates 




after the boost. Cells from the spleen were gated on B220+ cells and stained for the 
presence of PNA- and Fas-positive B cells. The mice immunized by the gD-wtFc, but 
not by the gD-mutFc or gD alone proteins, efficiently developed the comparable 
number (5% of total isotype-switched B cells) of FAS+PNA+B220+ B cells, 
suggesting the further differentiation into memory MBCs and LLPCs (Figure 3.6A). 
In addition, the gD-wtFc immunized FcRn KO mice failed to show the comparable 
number of FAS+PNA+B220+ B cells. Therefore, we conclude that FcRn-targeted 
mucosal delivery of the gD-wtFc induces the activation of GC B cells. 
 
Of the clonally expanded B cells, some differentiate to plasma cells that 
secrete antibodies at high rate and persist in niches in the bone marrow, whereas 
others become memory B cells. The latter can rapidly respond to antigenic 
restimulation and it has been suggested that they may contribute to maintaining the 
plasma cell pool and therefore serum antibody levels over prolonged periods of time. 
To determine whether antigen targeting to FcRn leads to long-lasting memory B cell 
immune responses, spleen cells isolated from 6 months post immunization were 
analyzed with Alexa647 labled gD protein. Memory B cells were barely observed 
after vaccination with control gD or PBS (Figure 3.6B). However, gD-wtFc 
immunized mice were shown to have a distinct population of the memory B cells in 
contrast to the gD-wtFc immunized FcRn KO or the gD-mutFc immunized WT mice. 
To determine whether antigen targeting to FcRn-mediated IgG transfer pathway also 
leads to long lived plasma cells that secret gD-specific antibodies, the number of IgG-
































Figure 3.5. Local immune responses induced by FcRn-targeted mucosal immunization. 
Immunization conditions are displayed at the top or bottom of each panel. 
(A). Detection of activated B cells in the germinal center (GC) in the gD-wtFc immunized 
mice by flow cytometry. Representative flow cytometric analyses of GC B cells among 
B220+ B cells in the MLN 7 days after immunization. Numbers are the percentage of 
activated GC B cells (PNA+FAS+) among gated B220+ cells. 
(B). Inducible bronchus-associated lymphoid tissue (iBALT) is formed in the gD-wtFc 
immunized mice. Frozen serial sections of the lung were stained with biotin-PNA (germinal 
centers, red) and anti-B220 (B cells, green), followed by Alexa 555-Avidin or 488 Fluro-
conjugated goat anti-rat IgG The nucleus is stained with DAPI (blue). Colocalization of all 
three red, green, and blue appears in white. The germinal center-like structure is shown in the 
mergered panel that appears in white color. The data are representative of sections from at 
least three independent mice. Images were originally obtained at 10× magnification. Scale 
bars represent 100 μm. Immunization conditions are displayed at the right. 
(C). HSV-2 gD-specific antibody response in bronchial lavage and vaginal secretions 
following the immunization. The nasal washings (left panel), bronchial lavage (middle panel) 
and vaginal washes (right panel) were obtained from mice on the 10 days after the boost and 
gD-specific IgG and IgA titers were determined by ELISA. Antibody titers for five mice from 
a representative experiment of three performed were quantified by endpoint titer. Titers of 
HSV2 gD-specific IgG antibody from serum and vaginal washes of naive mice always fell 
below the limits of detection and are omitted from the figure for clarity. The data shown are 
representative of three independent experiments. Asterisk (*) indicates significant difference 
among groups (P≤0.05).  
(D). Presence of HSV-2 gD-specific T lymphocytes in the lung. Lung cells isolated from 
mice 4 days after i.n. second immunization were incubated with 10μg/ml of gD. 
Lymphocytes were gated based on their forward scatter (FSC) vs. side scatter SSC profile. 
Intracellular staining for IFN-γ was performed after surface staining of CD4 and CD8 
molecules. The profiles shown are representative of three pooled mice from one of two 
separate experiments. Numbers in the quadrants indicate percentages of IFN-γ-secreting T 
lymphocytes from gated CD4+ and CD8+ T cells. (E). Increased presence of HSV-specific T 
lymphocytes in the vaginal epithelium after immunization. Lymphocytes were harvested from 
collagenase-digested vaginal tissues pooled from 3 normal or immunized mice 6 days after 
intravaginal inoculation of 104 pfu of virus. Intracellular staining for IFN-γ expression on 
CD4+ and CD8+ T cells was analyzed after gating on viable CD3+ lymphocytes. The 
numbers in each column show the percentage of IFN-γ-positive T lymphocytes from gated 
CD4+ or CD8+ T cells. Data shown are of a representative experiment of three repeat using 










We found the significant number of gD-specific IgG antibody-producing cells in the 
bone marrow of mice immunized with the gD-wtFc in comparison with that of other 
groups (Figure 3.6C).  
 
To further examine whether the increase in germinal centre B cells, antibody-
secreting plasma cells, and memory B cells correlates with an increase in gD specific 
IgG production, mice were bled six months, the longest point we tested, after the 
boost, and IgG antibody responses in sera were measured by ELISA. High titers of 
gD-specific IgG antibodies were elicited in mice immunized with the gD-wtFc, but 
not with the gD-mutFc or gD alone (Figure 3.6D), indicating the long persistence of 
gD-specific antibody after a mucosal immunization.  
 
FcRn targeted mucosal immunization induces long-term memory T cell 
responses 
An important feature of memory T cells is their proliferative potential upon 
reencounter with an antigen. To test if long-term memory T cells could be detected 
six months following the immunization, we measured CD4+ and CD8+ T cell 
proliferation by CFSE dilution in response to gD antigen stimulation.  Spleen cells 
isolated six month post-vaccination were CFSE-labeled and stimulated in vitro with 
the recall antigen (Figure 3.7). After 4 day incubation, the CFSE profiles were read on 

















Figure 3.6. Increased memory humoral immune responses in FcRn-targeted mucosal 
immunization. The groups of five mice were i.n. inoculation of proteins or PBS as indicated.  
(A). Accumulation of activated B cells in germinal center (GC) in the spleen of the gD-wtFc 
immunized mice. B220+PNAhighFAShigh cells are B cells that exhibit the phenotypic attributes 
of GC B cells. Representative flow cytometric analyses of GC B cells among B220+ B cells 
in the spleen 10 days after second immunization. Numbers are the percentage of activated GC 
B cells (PNA+FAS+) among gated B cells, and are representative of three independent 
experiments and are representative of three independent experiments.  
(B). Induction of gD specific memory B cells in the spleen. The frequency of gD-specific 
memory B cells was assessed 6 months post primary immunization. Memory B cells, defined 
as B220+ IgG (gD-specific)-surface+, present 6 months after the boost were analyzed by 
FACS. Purified gD proteins were labeled with Alexa Fluro647. Spleen cells (2 X 105) were 
isolated from 6 months post primary immunization and incubated with the 1 μg of Alexa 
Fluro647-labeled gD proteins. Numbers in the quadrants are the percentage of HSV-2 gD-
specific memory B lymphocytes from gated class switched IgD- IgM-B220+ B cells. Data are 
representative of three experiments on the same batch of immunized mice. (C). Long-term 
HSV gD-specific antibody-secreting cells in the bone marrow. Bone marrow cells removed 6 
months after the primary immunization were placed on HSV-2 gD-coated plates and 
quantified by ELISPOT analysis of gD-specific and IgG-secreting plasma cells. Data were 
pooled from two to three separate experiments with three mice in each experiment. The 
graphs are plotted based on the average ELISPOTs for replicate wells. Values marked with 
asterisk are significantly greater (P < 0.01) from the gD-wtFc fusion protein-immunized mice 
than those for other groups as indicated. No HSV-2 gD-specific and IgG-secreting plasma 
cells were detected in bone marrows from naive animals. 
(D) Durability of HSV-2 gD-specific serum IgG response. In two separate experiments, 
HSV-2 gD-specific IgG was quantified by ELISA in serum by endpoint titer from 3 mice at 6 














        We detected significant number of CD4+ (Figure 3.7A, upper panel) and CD8+ 
(Figure 3.7A, bottom panel) memory T cell proliferation in response to gD recall 
stimulation in the group of mice immunized with gD-wtFc, but not in any of the other 
groups, including the FcRn KO mice immunized by gD-wtFc proteins, indicating that 
the gD-specific T cells had maintained a significant proliferative potential at this late 
time point post-vaccination.  A recall IFN-γand IL -2 secretions within 48  hr of gD 
antigen restimulation were detected in spleen cells from mice immunized with the 
gD-wtFc, but not with other immunized groups (Figure 3.7B). Collectively, these 
results lead us to conclude that mucosal immunization by antigen targeting to FcRn is 
effective in eliciting long term memory T cell immune responses. 
 
DISCUSSION 
Mucosal subunit vaccines are assumed as most effective and safe agents to 
prevent or control the mucosal infections. However, to date, we are unable to develop 
such vaccines. One of the challenges of mucosal subunit vaccine design is lack of 
efficient delivery tools (Reviewed in chapter 1). In this study, we propose to target 
FcRn as a vehicle to deliver Fc fused antigen as mucosal subunit vaccine, given the 
fact that FcRn is capable of transporting IgG from apical to basolateral compartment 
of different mucosal barriers, like placenta and intestine. In this regard, we fused the 
Fc fragment of IgG2a with HSV-2 gD protein and intranasally applied such fusion 
protein to wild-type and FcRn KO mice respectively, and it turned out that FcRn can 
efficiently transport gD-wtFc fusion proteins across mucosal barrier, evidenced by the 






Figure 3.7. Long-lived gD-memory T cells to FcRn-targeted mucosal vaccination. 
C57BL/6 mice or FcRn KO mice were i.n. immunized with two doses of 20 µg fusion protein 
or gD. Representative flow cytometry profiles of three similar experiments with three mice 
per group were shown. Immunization conditions are displayed on the top or bottom. 
 (A). Proliferative capacity of gD-specific T cells six months post-vaccination.  Splenocytes 
were pooled from three control or vaccinated mice six month after the primary immunization, 
stained with CFSE, and stimulated in vitro with purified gD for 4 days. Cells were analyzed 
by flow cytometry, where CFSE dilution on CD4- and CD8-gated cells was used as a readout 
for gD-specific proliferation. Numbers are the percentage of CD4+ and CD8+ proliferating T 
cells. Data are expressed in CFSE histograms of fluorescence intensity versus the number of 
fluorescing cells, indicating the percentage of the cell population positive for CD4 and CD8 
antigen. Data are representative of two experiments on the same batch of immunized mice. 
(B). Cytokine secretions from re-stimulated spleen T cells. Spleen T cells were collected and 
pooled from three mice per group 6 months post-vaccination. Cells were restimulated in vitro 
specifically with purified gD protein.  Cytokines secreted into the culture supernatant were 
detected by ELISA. Data are representative of 3 experiments with 3 mice pooled in each 





The delivery function of FcRn was further verified by the fact that the gD-wtFc 
protein was failed to be transported across mucosal barrier in FcRn KO mice. In 
addition, the transported gD-wtFc in wild type C57/B6 mice was persisted much 
longer in the sera. However, it should be noticed that the detected fusion proteins in 
the mouse sera may not reflect the actual amount of fusion proteins transported in 
mice since we were unable to quantify the fusion proteins deposited in the different 
tissues and pinocytosed or endocytosed proteins inside of cells.  
         
        Preferably, an effective mucosal subunit vaccine should give both humoral and 
cell-mediated immunity, not only at the mucosal delivery site, but also all through the 
body, including systemic compartments as well as distal mucosal tissues from the 
mucosal immunization sites. Therefore, following the successful mucosal transport, 
we are interested in determining whether gD-Fc proteins directed to the FcRn-
mediated transport pathway can be perceived by the immune system and induce 
strong mucosal and systemic antigen-specific antibody and cellular immune 
responses.  Our data clearly showed that FcRn-targeted delivery of mucosal subunit 
vaccine was able to mount strong systemic and mucosal humoral immune responses. 
Likewise, the gD-wtFc fusion proteins that we tested also induced broad and strong 
cellular immune responses, shown as the induction of IFN-γ–producing CD8+ and 
CD4+ T cell responses in both lymphoid tissue and mucosal sites. We also determined 
that FcRn was essential for such efficacy by employing both mutant fusion protein 
and FcRn knockout mice. Thus, the use of FcRn targeting greatly increases the 




when given together with CpG stimuli for DC maturation and mucosal tolerance 
disruption. In terms of humoral responses, we noted that the FcRn-targeted mucosal 
vaccine was superior in inducing the high titer of IgG antibody production in sera 
relative to the gD-mutFc or gD alone (Figure 3.3A). IgG2a, but not IgG1, is a major 
isotype detected (Figure 3.3B). This is not surprising because the helper type 1 
cytokine IFN-γ is associated with the production of IgG2a, whereas the helper type 2 
cytokine IL-4 supports switching to IgG1. In this study, IL-4 was less produced by T 
cells (Figure 3.4B).  
 
It is crucial to notice that an important consequence of FcRn-targeted mucosal 
delivery of subunit vaccine elicited strong mucosal immune responses. This 
conclusion is supported by several evidences, such as the existing of significant 
amount of IgG antibody in the lung lavages and vaginal washings and IgA in the 
trachea wash, and IFN-γ producing CD4+ and CD8+ T cells in the lung and vaginal 
tissues in the gD-wtFc immunized mice. This observation was paralleled by the 
higher numbers of activated B cells in the germinal centers found in MLN (Figure 
5A) and the presence of induced bronchial lymphoid tissues (iBALT) in the lung 
tissue (Figure 3.5B) of the gD-Fc immunized mice. Appearance of the germinal 
centers in MLN as well as iBALT in the lung is best explained by local induction due 
to the presence of the transported gD-wtFc antigen in the MLN and lung. The IgG 
detected in BAL may be transported from serum to the luminal secretions actively by 
FcRn. Of note is the observation that BAL- or vaginal IgG levels were much higher 




middle panel). Indeed, IgG appears a major isotype of immunoglobulins in the lower 
respiratory tract and reproductive tracts (253). Thus, the IgG antibodies detected in 
BAL and vaginal washings may be both locally produced as well as serum-derived. 
Overall, both locally and serum-derived IgG are important for controlling viral 
infection in the lower respiratory and genital tract. We conclude that antigen targeting 
to FcRn combined with a mucosal adjuvant produces strong mucosal T cell as well as 
humoral immune responses. Considering that an efficient protective vaccine should 
induce mucosal in the mucosa in order to hinder pathogen penetration and spreading, 
the data presented here suggest that FcRn-targeted mucosal vaccine delivery may 
provide a very promising technology for the development of protective mucosal 
vaccines in humans. 
  
        Notably, FcRn-targeted mucosal immunization can confer protection against 
mucosal challenge by virulent HSV-2 virus. Mice inoculated intranasally with an 
attenuated strain of HSV-2 develop vigorous antibody and cell-mediated immune 
responses that have been shown to protect the animals from death following 
intravaginal inoculation with lethal doses of fully virulent HSV-2. We take advantage 
of this system as a paradigm to examine whether the immune responses elicited by 
FcRn-mediated subunit vaccine delivery via intranasal inoculation for the protection 
of the distal vaginal mucosa. The gD-wtFc subunit vaccine described in the present 
study induced complete protection and significantly reduced virus shedding in the 
vaginal lumen, but not the gD-mutFc or gD alone subunit vaccine, throughout the 




mice were failed to provide the complete protection (Figure 3.2A). These data 
indicate that protection is FcRn dependent. Several mechanisms may account for the 
role of the immune responses elicited by this novel pathway in protection of the distal 
vaginal mucosa. First, mucosal and systemic humoral immune responses elicited by 
FcRn transported gD-Fc may play an important protective role. This conclusion was 
supported by the evidences that the significant amount of gD-specific antibody 
appeared in the vaginal secretions (Figure 3.5C) and the sera passively transferred 
from the gD-Fc immunized mice conferred high level of protection. It has been 
reported (254) that IgG was the main protective antibody in mouse vaginal secretions 
after vaginal immunization with attenuated herpes simplex virus type 2 . Second, T 
lymphocytes were present in the vaginal epithelium of HSV-2 infected mice at a time 
coincident with virus clearance. In the current study, the gD-wtFc subunit vaccine 
induced a high frequency of IFN-γ secreting CD4+ and CD8+ T cells in either the lung 
(Figure 3.5D) or vaginal tissues (Figure 3.5E). The mechanisms by which such IFN-
γ-positive cells exert their function may be diverse. IFN-γ is clearly indispensable for 
resistance to HSV-2 infections (255). It is also possible that the strong CD4+ T cell 
responses induced by FcRn targeting  provides direct resistance, e.g., through the 
direct lysis of MHC class II– bearing infected epithelial cells. Another possiblility is 
that CTL may contribute to the protection of HSV-2 infectin in the vaigina.Another 
interesting consequence of the FcRn-targeted vaccine was that protective CD4+ T cell 
immunity was elicited at a mucosal surface of the genital tract, which was distal to the 
intranasal vaccination site. Several studies found that mucosal immunization using the 




the female genital tract. Perhaps intranasal immunization stimulates cells in the nasal 
lymphoid tissue (NALT) and its draining cervical lymph nodes, MLN,  leading to the 
migration of antibody secreting cells and T cells generated in the airways into the 
female genital tract (256). 
 
FcRn targeted mucosal immunization elicits long-lived memory immune 
responses. Immunological memory to a specific vaccine antigen or pathogen is a 
hallmark of the vertebrate immune system. It is characterized by increased levels of 
effector T and B cells and, functionally, the ability to respond faster and more 
vigorously to a second encounter with the pathogen or vaccine antigens than during 
the primary response (79). Hence, an important success criterion for any vaccine is 
the formation and maintenance of a reservoir of memory lymphocytes of both 
adequate size and quality to maintain efficient immune surveillance for prolonged 
periods. A popular paradigm theory is that continuous antigen exposure provided by a 
live viral or bacterial vaccine would be necessary for the maintenance of efficient 
immunological memory. An obstacle for the successful implementation of any 
subunit vaccine is the production and maintenance of a pool of memory lymphocytes 
with adequate size and duration. This feature has been a special cause of concern in a 
subunit vaccine development. Hence, it has been extremely difficult to implement 
subunit strategy to many global infections because its preparation could elicit high 
levels of immunity immediately after vaccination but that immunity waned rapidly 
over time. However, the most striking feature is that the FcRn mediated delivery of 




gD-specific plasma cells and memory B and T cells at least 6 months post-
vaccination (Figures 3.6 and 3.7).  Long-lived plasma cells in the bone marrow 
(Figure 3.6C) and memory B cells in the spleen (Figure 3.6B) should explain for the 
appearance of high level of serum antibodies (Figure 3.6D). Given the relatively short 
half-life of immunoglobulin in vivo, antibodies have to be continuously secreted by 
plasma cells. In the cases of polio and diphtheria vaccines, serum antibody levels are 
maintained at high levels for prolonged periods of time after vaccination. Although 
the reason for the high memory T cell activity is not completely clear, cytokine IL-2-
producing memory T cells formed in the responding T cell population (Figure 3.7B) 
may be important since IL-2 plays an important role in the successful long-term 
survival of primed CD4+ T cells in vivo, and the expression of IL-2 has been 
associated with predominantly central memory T cells (257). In addition, the FcRn 
per se, in addition to be a highly efficient epithelial transporter for the gD-wtFc, acts 
as a protector for prolonging the half-life of Fc-fused vaccine antigens (258). It is 
generally assumed that a slow, low-level release of vaccine antigen over prolonged 
time can promote good long-term memory responses. Future studies are planned to 
address the potential role of the long-term memory response after the gD-wtFc 
subunit vaccination in modulation of reactivation from latency. These important 
features may represent a major advantage for the practical implementation of this 
FcRn-targeted mucosal vaccine in humans.     
 
Overall, given the fact that the FcRn targeted mucosal vaccination differs 




mice in terms of protection results, mucosal and systemic immune responses, 
cytokine expression profiles, and the long-term memory and protective efficacy,  this 
study shows that mucosal administration of the vaccine antigens targeted to FcRn is 
sufficient to elicit strong and long-lasting mucosal and systemic antibody and T cell 
responses as well as immune memory specific for vaccine antigens. The knowledge 
gained from this study will be useful in development of effective mucosal vaccine 
strategies for broad mucosal pathogens, such as human immunodeficiency virus-1, 
Chlamydia, influenza etc., that infect at or invade across mucosal surfaces. Taken 
together, these promising results may lay the groundwork for introducing FcRn-
targeted vaccines to mucosal infections, such as HIV and HSV-2, also may emerge as 
a realistic and safer alternative implementation to live virus or bacterium vaccines in 








Chapter 4: Summary and Perspectives 
        Since FcRn was cloned in 1989 by Neil Simister, much progress has been made 
to elucide the biological characteristics of FcRn. To date, FcRn is defined as a unique 
IgG Fc receptor and member of MHC class I family, due to following features: (1) 
FcRn plays essential roles in both IgG homestasis and IgG transport; (2) FcRn binds 
to IgG exclusively at acidic pH condition; (3) FcRn mainly resides in the endocytic 
vesicles of cells; and (4) FcRn transports IgG across polarized mucosal barrier bi-
directionally. However, many questions remain unknown. Which signals determine 
FcRn to transport IgG across mucosal barrier bi-directionally? What kind of 
epigenetic modifications regulate FcRn expression in newborn and adult intestine? 
What are exact roles of FcRn in maintaining the autoantibody in autoimmune diseases 
? What kind of roles does FcRn play in the process of viral or bacterial infection at 
mucosal sites?    
 
        Particularly, I am interested in how FcRn traffick into endosomes, because the 
residency of FcRn in endosomes is the prerequisite for its IgG protection and 
transport function. In Chapter 2, by utilizing the combination of a variety of 
biochemical and cell biology tools, we identified that the putative dilucine motif 
within the cytoplasmic domain of FcRn was involved in the FcRn trafficking into 
early endosomes. Furthermore, we also found that MHC class II associated invariant 
chain can interact with FcRn and modulate FcRn trafficking into both endosomes and 
lysosomes. This is demonstrated by multiple approches: FcRn can be specifically 




mouse) double transfected HeLa cells or CHO cells. This also holds true for primary 
cultured human PBMCs or mouse bone marrow derived dendritic cells. More 
significantly, such interaction can regulate FcRn trafficking into both early 
endosomes and lysosomes. FcRn has been known as early endosomal receptor, but 
our data challenged this dogma, arguing that in the absence of invariant chain like in 
epithelial cells at steady state, FcRn mainly resides early endosomes, however in the 
presence of invariant chain, such as in the APCs which constitutively express 
invariant chain or epithelial/endothelial cells at inflammatory condition in which the 
expression of invariant chain is dramatically upregulated, a significant fraction of 
FcRn was diverted from endosomes to lysosomes. This notion was further confirmed 
by the observation that FcRn seldom trafficks into lysosomes in the bone marrow 
derived dendritic cells (mouse) or PBMC derived dendritic cells (human) when 
invariant chain expression was abolished by gene knockout or silence. Our data 
discover that invariant chain expands the boundary of FcRn residence.  This was 
surprising, because invariant chain is known as MHC class II but not MHC class I 
chaperon. 
 
  Nevertheless, the biological significance of FcRn trafficking into lysosomes is 
unkown. However, by virtue of FcRn’s IgG protection and transport function, we can 
propose the following hypothesises. First, FcRn may extend its IgG protection 
function into lysosomes, building up the second line of IgG protection, which is 
potentially important for the protection of pathogen specific IgG during infection. 




the lysosomal traffic of FcRn. Because normal IgG likely occupy most FcRn in early 
endosomes due to a high concentration, anti-micorbial IgGs would most likely be 
delivered to lysosomes where lysosomal FcRn may capture the antigen specific IgG 
and transport FcRn-IgG complex out of cells via exocytosis. However, such a 
hypothesis needs to be carefully tested in the future. Nontheless, FcRn may also 
protect normal IgG in lysosomes. This hypothesis may be addressed by comparing 
the serum IgG level between wild type and Ii knockout mice in the future under the 
physiological or inflammatory conditions . Second, since MHC class II are most 
efficiently targeted into proximity with antigenic peptides by Ii chain in antigen 
presenting cells (APCs); it is interesting to bring into perspective of the known 
functions of Ii in conventional APCs in order to understand the role of FcRn/Ii 
association in influencing antigen presentation. Our previous findings show that the 
FcRn is expressed in Mφ and DCs (153). Since FcRn appears to associate with Ii 
chain, FcRn and MHC class II might occupy the same acidic compartments. In 
Macrophages and DCs, FcγRs can promote the internalization of immune complexes 
into the endosomes and lysosomes to increase the efficiency of MHC class II 
presentation to CD4+ T cells (236). FcRn, on the other hand, may mediate the antigen 
presentation by binding the immune complexes in these antigen processing 
compartments. The evidences that FcRn is able to bind immune complexes (65) and 
IgG in the pH range of endosomes and lysosomes (Zhu et al., unpublished data) 
support this probability. Therefore, the association of Ii chain and FcRn could further 
influence the antigen presentations. Third, FcRn was involved in IgG-mediated 




It would be interesting to know whether FcRn-Ii association in the neutrophils 
mediates the translocation of FcRn into the phagolysosomes. 
 
        FcRn is known as the only IgG transporter among Fc receptors, which can 
shuttle IgG across mucosal barrier bi-directionally. In Chapter 3, we investigated 
whether we can use FcRn as vehicle to transport viral-immunogen-fused Fc from 
mucosal surface to lamina propria to induce protective immunity to combat mucosal 
viral infections. This is of great significance because so far we are in great need but 
lack of safe and effective mucosal vaccines (209). In this project, we used herpes 
simplex virus type II as mucosal infection model, and we fused HSV-2 envelope 
protein gD with Fc fragment of mouse IgG2a. It was observed that such fusion 
protein can be efficiently transported by FcRn from mucosal lumen to the circulaton. 
More significantly, such transport can induce strong systemic and mucosal immunity, 
including both cellular and humoral immunity, evidenced by the induction of antigen 
specific CD4+, CD8+ T cell and antibody. As expected, the much stronger immunity 
was induced in wild type fusion protein intranasally administrated wild type B6 mice 
but not in FcRn knockout mice, mutant protein and gD immunized mice. In addition, 
we also observed that strong immune memory including long lived plasma cells, 
memory B cells and memory CD4+ and CD8+ T cells was left behind and lasted a 
long period. Most important, wild type mice can be completely protected from IVAG 
lethal viral challenge after intranasal immunization. Although we analyzed many 
aspects of immune responses induced by Fc fused protein in details, some 




interest to know what types of dendritic cells or macrophages uptake fusion proteins 
in the lamina propria. Different subsets of dendritic cells have been reported to induce 
the different consequences of immune responses (190). Second, we have shown that 
the fusion protein can induce strong CTL responses, it is reasonable to determine 
whether CD8α+ dendritic cells can acquire our fusion protein because CD8α+ DCs 
are known as lymphoid residential subsets, specialized in the crosspresentation of 
antigens (259). Third, it would be interesting to investigate the protection through 
respiratory challenge with respiratory virus models, like influenze virus infection. In 
this regard, more detailed information of mucosal CTLs and antigen secreting cells 
can be documented. Collectively, our data revealed that FcRn-IgG transfer pathway is 
superior for mucosal subunit vaccine delivery. This finding would be of important 
value because we are in great need for safe and effective mucosal vaccines, in 
particular for STDs, like HSV-2 and HIV infections. Subunti vaccine is the safetest 
one, but so far we still do not have good candidates for mucosal subunit vaccine due 
to practical obstacles (209). Our study may shed light on the development of effective 
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